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Class switch Recombination (CSR) also known as Immunoglobulin (Ig)
Class switching is a genomic recombination/deletion reaction that diversifies the
effector component of the antibody response but preserves antigen specificity.
CSR is initiated by the enzyme activation induced cytidine deaminase (AID), which
produces nucleotide mismatches in actively transcribed immunoglobulin heavy
chain (Igh) switch donor and acceptor DNA. The 3’ Regulatory Region (3’RR), a
prototypical super-enhancer located at the 3’ of the Igh locus, is essential for
acceptor switch region transcription, but the mechanism by which it regulates this
process is not well defined.

After targeting by AID, nearby mismatches in the donor switch region are
processed into DNA double strand breaks (DSBs), translocated to DSBs in the
acceptor switch region, and ligated through the DNA Damage Repair (DDR)
pathway, non-homologous end-joining (NHEJ). Critical components of CSR are
53BP1 and its effector RIF1 because they inhibit end resection to promote NHEJ

and oppose competing pathways in DDR. However, the mechanism by which RIF1 effects
end-protection in CSR and binds to 53BP1 is still unknown

In these studies, I identified a novel component of the RIF1 interactome, ZMYND8,
a chromatin reader and transcriptional repressor that binds to RIF1 and facilitates
effective CSR. Unexpectedly, ZMYND8 promotes CSR independently of RIF1. In B cells,
ZMYND8 binds active promoters and super-enhancers, including the Igh enhancer the
3’RR. ZMYND8 controls 3’RR activity by regulating polymerase loading. In its absence
there is increased 3’ RR polymerase loading and decreased acceptor region transcription
and CSR. Thus, ZMYND8 controls CSR by regulating the activity of the 3’ Igh superenhancer.
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Chapter 1: Introduction
1.1 Antibodies and the Adaptive Immune System
Organisms need to defend themselves against a wide variety of potential
pathogens and foreign organisms. While a limited number of P/MAMPs
(pathogen/microbe associated molecular patterns) like lipopolysaccharides are
genetically hardcoded to be innately recognized as foreign, our bodies rely on the
adaptive immune system to respond to novel and diverse molecular patterns
presented by pathogens. A central challenge of the adaptive immune system is
thus how to create specifically tailored but potentially infinitely variable targeting of
these patterns. When the adaptive immune system is able to recognize such a
molecular pattern as foreign, it is termed an antigen.

B cells are able to recognize and target such antigens by creating antibodies. The
potential antibody-antigen repertoire in humans is immense > 1011(Glanville, Zhai,
Berka et al. 2009). However, the actual repertoire size is less than that because it
is functionally limited by the total number of B-cells present in the body at a given
time, overlapping specificity for antigens (as a result of clonal expansion and
diversification of selected B cells), and limited encounters with the antigens
themselves. Regardless of these limitations, the size of the human genome is only
3x109 bases and consequently, diversification of antibodies by B cells is
accomplished by the combinatorial rearrangement of multiple gene segments. The
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induction, regulation, and translocations of these gene segments to produce
effective antibodies involves elements unique to the immune system (formation of
the breaks) and processes ubiquitous to all cells of the body (DNA repair).

Structure and Function
An antibody or immunoglobulin (Ig) is the secreted form of a B cell receptor (BCR).
They can bind to a wide diversity of antigens and a limited group of effector
molecules and cells.
N

N

C

C

Figure 1 Antibody/Immunoglobulin (Ig) Molecule
Igs are proteins secreted by B cells / plasmablasts. Four polypeptide chains
comprise the antibody. (LEFT) The blue regions are the heavy (IgH) chains and
the grey regions are the light (IgL) chains. Each pair of heavy and light chains is
identical to the other for a particular B cell. Disulfide bridges, indicated by black
lines, link the four chains. Different Ig classes have different structures. (RIGHT)
The N-termini of the heavy and light chains are indicated by N, the C-termini of the
heavy chains are indicated by C. Red highlights the variable region of the heavy
chain (VH). Green highlights the constant region of the heavy chain (CH). Orange
highlight the variable region of the light chain (VL). Purple highlights the constant
region of the light chain (CL).
2

Igs are functionally divided into the variable and constant regions. The variable
region comprised of the VH and VL is diversified through the V(D)J recombination
and later somatic hypermutation (SHM) reactions. The constant region is
comprised of the CL domain, kappa or lambda in mice and humans, and remains
fixed for a particular antibody. It is also comprised of the CH which confers the
particular isotype to an antibody. The diversity generating reactions VDJ
recombination and SHM do not alter the constant region, but the CH region, which
defaults to IgM, can undergo the process of class switch recombination (CSR). In
CSR, IgM can be switched to IgG, IgA, IgE or any of their subclasses (identified by
a numerical subscript after the class letter). Functionally, the ability to bind to
different antigens is due to the variable domain, which comprises about the first
110 amino acids of the N-terminus. The ability to interact with effector molecules
and cells is mediated by the constant domain. While every clonally derived
antibody has a unique variable region, the constant region is common to all
antibodies of that particular isotype.

Primary Diversification: V(D)J Recombination
The initial variability of an antibody derives from V(D)J recombination. In the
germline, the immunoglobulin locus has multiple different gene segments. During
the development of B and T cells, one copy of each segment is retained to produce
a functional BCR (B-cell receptor, essentially a membrane bound version of the
antibody encoded by that cell) or TCR, respectively. The other segments are
3

deleted through a recombination-deletion reaction (Brack et al. 1978), (Kurosawa
et al. 1981). This gene re-arrangement is fundamentally a controlled translocation
event with programmed DNA damage and ligation (Tonegawa 1983; (Schatz & Ji,
2011)).

Although this is a process that is controlled spatially and temporally within the
body, the selection of V(D)J segments for recombination is random. There are >
3.5 million possible combinations for an antibody however, in actuality certain
combinations of V(D)J heavy chain and VJ light chain segments do not make
stable BCRs and thus those combinations never appear in the human repertoire.
In addition to the combinatorial diversity, the enzyme terminal deoxynucleotide
transferase (TdT) add nucleotides at the joining junctions. V(D)J recombination is
mediated by the RAG1/RAG2 recombinases.

Secondary Diversification
Further antibody variability differs from V(D)J recombination in two key elements.
First, the initiating enzyme is Activation Induced Cytidine Deaminase (AID) and not
the RAG complex. Second, the diversification occurs after B cells have developed,
when they are in the periphery—not the originating bone marrow, and after they
have encountered an antigen.

4

Somatic Hypermutation (SHM)
After the initial rearrangement of gene segments takes place in B cells in the
central lymphoid organs (bone marrow), the immunoglobulin variable region can
further diversify in a process termed somatic hypermutation (SHM). SHM takes
place in the peripheral lymphoid organs. Point mutations are introduced in the
variable region, which increases sequence diversity. B cells interact with T cells in
the germinal center. B cells in which SHM has resulted in variable regions with
better affinity for the antigen presented by a T cell are induced to divide and mutate
more. The process repeats over many cycles, with B cells with high affinity for a
specific antigen evolutionarily outcompeting those that do not. This entire process
is termed affinity maturation.

Class Switch Recombination (CSR)
The previous three mechanisms: V(D)J recombination, junctional diversity, and
SHM all alter the variable region and therefore affect the specificity of the antibody
for an antigen. The last mechanism of antibody diversity in mouse and humans,
isotype switching also known as class switch recombination (CSR), retains the
antigen specificity of an antibody while changing the effector function. This is
accomplished by switching the default constant region of the heavy chain locus
(Constant mu - Cμ and also Constant delta - Cδ) to another constant region. The
following sections will detail the different isotype classes and functions produced
by CSR, and the mechanism by which CSR occurs.

5

Figure

2:

IgH

locus

recombination/deletion

during

Class

Switch

Recombination
(A) Locus arrangement and antibody production: The IgH locus is arranged on
chromosome 12 of mice. The VDJ region immediately precedes the mu, delta,
gamma3, gamma1, gamma2b, gamma2a, epsilon, and alpha heavy chains (blue,
green, green, green, green, maroon, orange, respectively). Each heavy chain
(except for delta) has an intronic promoter (colored arrow if activated), repetitive
switch region (colored circle), and heavy exons (colored rectangle). Transcription
through mu and delta is constitutive in naïve B cells. mRNA from the VDJ region
and CH region combine to form the Ig heavy chain (color correspond designated
antibody at right).
(B) Activation: with activation in vivo or ex vivo by specific cytokines (here LPS +
IL-4), germ line transcripts (sterile, non-coding) GLT appear at the targeted
acceptor Ix-Sx-Cx locus.
(C) Targeting by AID: AID is guided to the switch regions through multiple
mechanisms detailed later. At the transcribed switch region (donor and acceptor)
AID deaminates cytosine to uracil. Multiple deaminations lead to double-strand
break formation.
(D) Synapsis and Ligation: the upstream switch region synapses with its
downstream counterpart and joins to form a hybrid switch region (ellipse). The
recombined locus will now produce antibodies from the downstream / switched
heavy chain (here IgG1).
(E) Post-switch excision: the excised genomic region is circularized. Transcripts
from the still active downstream intronic promoter can be detected.
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Immunoglobulin Heavy Chain (CH) Isotypes: Structure and Function
The different CH regions of antibody isotype classes determine the interaction
partners and function. First, some isotypes can bind cell surface receptors and
modulate the immune response (i.e. IgG1 and IgG3 bind Fcγ receptors on
phagocytic cells) (Nimmerjahn, 2008). Second, some isotypes can bind Fc
transporters to actively transport antibodies (i.e poly-immunoglobulin receptors on
mucosal epithelial cells transport IgA to mucous secretions, tears and milk, and
IgG to the fetal blood circulation by placental transfer) (Kaetzel, 2005). Third, the
Fc can bind the C1q protein to activate complement. Fourth, Fc can bind to other
Fcs to form multimeric structures (i.e. IgM forms pentamers in humans and mice,
IgA forms dimers as the mucosal secretory form) (Stavnezer, Guikema, &
Schrader, 2008).
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1.2 Steps of CSR

Abstractly, CSR is an irreversible change in protein expression. The switch from
IgM to another isotype (IgG, IgA, IgE) means that a switch in gene expression
occurs and this switch has multiple possible outcomes. Fundamental questions in
CSR are thus: (1) what activates CSR, (2) what causes isotype specificity, and (3)
how is this mediated at a genetic level?

Transcription and CSR
Early on, CSR was found to be dependent on transcription. In an IgM+ B cell line,
I.29 lymphoma, CSR to the IgE, IgA, and IgG2a isotypes correlated with the
expression of non-coding, sterile transcripts to the corresponding CH region
(Stavnezer-Nordgren, 1986).

Similarly, an Abelson murine leukemia virus

transformed pre-B cell line showed analogous sterile transcripts when switching to
IgG2b (Yancopoulos, 1986). In the next few years, GLTs were identified in primary
B cells along with the cytokine combinations that corresponded to specific isotype
switching. LPS stimulates GLT gamma2b and gamma3 and thus switching to IgG2b
and IgG3 (Lutzker, 1988), (Severinson, 1990), (Snapper & Paul, 1987). LPS and
IL-4 stimulates GLT gamma1 and epsilon and thus switching to IgG1 and IgE
(Lutzker, 1988), (Snapper & Paul, 1987), (Stavnezer, Guikema, & Schrader, 2008).
TGF-β stimulates GLT alpha and switching to IgA (Lebman, 1990) (Shockett &
Stavnezer, 1991). Confirming the necessity of GLT for CSR, deletion of the intronic
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promoter for GLT gamma1 eliminated CSR to IgG1 (Jung, 1993); likewise, the
replacement of the GLT gamma2b promoter, exon and splice donor site with a
NeoR gene in the opposite transcriptional orientation eliminated CSR to Ig2b
(Zhang, Bottaro, Li, Stewart, & Alt, 1993). However, other transcriptional elements
could substitute for intronic promoter. Replacement of the Iα and exon by a
hypoxanthine phosphoribosyltransferase (HPRT) minigene in the correct
transcriptional orientation was sufficient for CSR to IgA (Harriman, Bradley, Das,
Rogers-Fani, & Davis, 1996).

Transcription and Mutations
Transcription was found to strongly correlate with [what would later be identified
as] AID dependent mutations. Rearranged IgH loci had mutation signatures similar
to SHM. However, in addition to base pair substitutions found in the variable
regions, the switch regions also had deletions, insertions and inversions (Dunnick,
Wilson, & Stavnezer, 1989), (Dunnick, Hertz, Scappino, & Gritzmacher, 1993). By
inserting a promoter upstream of CH regions, mutations could be induced in the
normally unmutated constant region (Peters & Storb, 1996). These mutations were
later found to be AID-dependent and located 3’ of the intronic enhancers, which
are 5’ of the recombination sites (Nagaoka, Yamamura, Kinoshita, & Honjo, 2002)
(Petersen, et al., 2001). Combination UNG-/- Msh2-/- mice allowed increased
sensitivity to detect AID targeting because deaminations could not be correctly
repaired. Transcription was found to be essential for mutations in dsDNA in vitro
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(Chaudhuri, et al., 2003) and in bacteria (Ramiro, Stavropoulos, Jankovic, &
Nussenzweig, 2003). In vivo, mutations began 150 bp 3’ of the Transcription Start
Site (TSS) of the S region intronic promoter and continued even beyond the S
region (Xue, Rada, & Neuberger, 2006). Like SHM, there appeared to be no strand
bias and the mutation signature conformed to the RGYW motif.

Discovery of AID as the mutational enzyme
AID was discovered as one of four factors upregulated in a screen of the mouse
CH12F3 (CH12) B cell lymphoma line (Muramatsu, et al., 1999). Specifically,
CH12 cells were activated to undergo CSR from IgM+ to IgA+ and cDNA
subtracted, expressed genes were compared to unactivated (IgM+) cells. AID was
selected for further study because it showed a dramatic increase in transcription
from practically nothing in unactivated CH12 cells to at least a 10-fold increase in
activated CH12 cells. AID was subsequently proved necessary for SHM and CSR
in mice (Muramatsu, et al., 2000) and humans (Revy P, et al., 2000). It was also
shown necessary for gene conversion (a mechanism of generating antibody
diversity not present in mice or humans, but utilized by birds, rabbits, cows and
pigs) in chickens (Arakawa, Hauschild, & Buerstedde, 2002).

Mechanism of Mutation by AID
AID was first recognized as a homolog of APOBEC1 (apolipoprotein B mRNA
editing catalytic polypeptide 1) (Muramatsu, et al., 1999). APOBEC1 is a RNA
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deaminase, which deaminates cytosine to uracil. AID catalyzes the same reaction
but on DNA (Figure 3).

NH2

O
H 2O

NH3

N

HN
AID - Zn+

O

O

N

cytosine

N

uracil

Figure 3: Deamination of cytosine to uracil by AID
AID deaminates cytosine to uracil. Note: the name activation induced cytidine
deaminase (AID) is actually a misnomer. Because AID acts on DNA, not RNA the
technically correct name should be activation induced deoxycytidine deaminase.
The cytidine is a holdover from the discovery of AID which was thought to act on
RNA due to its homology to APOBEC1.

Switch Regions: Sites of Recombination
Switch regions are sequences of G-rich, repetitive DNA elements ranging from 112 kb long and precede the constant regions (with the exception of Cδ). The
regions contain many RGYW repeats, the preferred deamination targets of AID
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(Rogozin & Kolchanov, 1992). It was postulated that these regions are the target
sites of recombination because, most IgH locuses of isotype switched cells showed
junctions between upstream Sμ and downstream acceptor (SX) regions (Matthews,
Zheng, Di Menna, & Chaudhuri, 2014). Switch regions were shown to be the sites
of recombination when the deletion of Sγ1 completely abolished CSR to IgG1 but
left other isotypes unaffected (Shinkura, Tian, Chua, Fujiwara, & Alt, 2003).

AID Targeting
Recombination at the switch regions requires a DNA double-strand break (DSB)
intermediate. However, AID was found to only act on single-stranded DNA
(ssDNA) in vitro (Bransteitter, Pham, Scharff, & Goodman, 2003), (Chaudhuri, et
al., 2003), (Dickerson, Market, Besmer, & Papavasiliou, 2003), (Petersen-Mahrt,
Harris, & Neuberger, 2002), (Pham, Bransteitter, Petruska, & Goodman, 2003),
(Ramiro, Stavropoulos, Jankovic, & Nussenzweig, 2003), and (Sohail, Klapacz,
Samaranayake, Ullah, & Bhagwat, 2003). A solution was proposed where the
transcribed S region, could hybridize with the template strand and form a R-loop
(a RNA:DNA hybrid) which would free the non-template strand as ssDNA for AID
mutation. R loops were experimentally implicated in CSR when a synthetic S
region known to form R loops in vitro facilitated CSR when placed in cells. But, if
the sequence was transcribed in the reverse orientation, precluding R loop
formation, CSR decreased greatly (Shinkura, Tian, Chua, Fujiwara, & Alt, 2003).
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Although R loops are necessary for CSR, it fails to explain how AID targets the
DNA strand still in the RNA:DNA hybrid (the template strand). It was identified that
the RNA exosome accumulates with the IgH locus in an AID dependent manner,
associates with AID and is necessary for efficient CSR (Basu, et al., 2011). The
exosome complex was sufficient to deaminate both strands of a transcribed SHM
substrate in vitro. It is proposed that the exosome degrades the R-loop, an upon
collapse the DNA may misalign, resulting in ssDNA on both the template and nontemplate strand (Matthews, Zheng, Di Menna, & Chaudhuri, 2014).

AID is actually a fairly inefficient enzyme. Mutations in the variable regions only
occur at a frequency of about 1 mutation per 1 kb per cell per generation (Yamane,
et al., 2011). While an inefficient enzyme is desirable for the rest of the genome to
prevent potentially oncogenic AID off-target activity (Casellas, et al., 2016), the
mutation rate must be higher to effect the theoretical minimum 4 mutations to
induce CSR within a reasonable time.

In addition to transcriptional dependence and a high concentration of RGYW motifs
present in the switch region, B cells target AID to the switch regions through two
other key mechanisms. It was found that Spt5, a factor associated with stalled RNA
polymerase (Pol II) recruits AID to sites of stalled transcription (Pavri, et al., 2010).
Additionally, the GLTs undergo RNA processing and in the process excise intronic
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segments. These spliced regions are debranched and form G-quadruplexes which
target AID to S region DNA (Zheng, et al., 2015).

1.3 DSB formation in CSR

DSBs are Essential for CSR
Although AID is essential for SHM and CSR, it does not directly cause the DNA
breaks required for CSR. Instead processing of the deamination site can lead to
non-mutating repair, mutations as in SHM, and DSBs as in CSR.

40 years ago, DSBs were postulated to be essential for CSR (Honjo & Kataoka,
1978). A model called allelic deletion, was theorized by examining the frequency
of heavy chain deletions in mouse myelomas. By comparing the heavy chain
deletions with the corresponding isotype expressed the germline order of heavy
chain segments could be inferred. A looping out mechanism was suggested to
account for these rearrangements. DNA loops as a result of immune recombination
events were detected from variable regions in T cell receptor rearrangement
(Fujimoto & Yamagishi, 1987), (Okazaki, Davis, & Sakano, 1987), (Okazaki &
Sakano, 1988); from variable regions in the IgH locus (Abe & Shiku, 1989), (Toda,
Hirama, Takeshita, & Yamagishi, 1989); and from variable regions in the IgL locus
(Toda, Hirama, Takeshita, & Yamagishi, 1989), (Mccormack, et al., 1989). The
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proposed excision products in CSR were finally able to be isolated (von Schwedler,
Jack, & Wabi, 1990), (Iwasato, Shimizu, Honjo, & Yamagishi, 1990), (Matsuoka,
Yoshida, Maeda, Usuda, & Sakano, 1990), (Yoshida, et al., 1990). Recombination
products due to CSR were fundamentally different than those derived from variable
regions. All variable regions had defined breakpoints encompassing V(D)J (in the
heavy chain, VJ in the TCR and light chain), but CSR has breakpoints that spanned
the entire multi-kilobase switch regions. Thus, breaks in the variable region are
specific, but breaks in the switch regions are variable.

Direct evidence of the DSBs at the switch regions came from Ligation-Mediated
PCR (LM-PCR). Blunt DNA DSBs were detected at Sγ3 in mouse splenic B cells
(Wuerffel, Du, Thompson, & Kenter, 1997), S μ in human B cells (Catalan, et al.,
2003); but staggered breaks were found to be much more abundant (Rush,
Fugmann, & Schatz, 2004). These breaks were found to be AID and UNG
dependent (Schrader, Linehan, Mochegova, Woodland, & Stavnezer, 2005).

Factors involved in DSB repair were also detected at the IgH locus, specifically γH2AX foci were found at IgH in ex vivo stimulation of splenic B cells, and these foci
were also AID-dependent (Petersen, et al., 2001). Since that time, many DNA DSB
repair factors were discovered to contribute to CSR [reviewed in: (Daniel &
Nussenzweig, 2013), (Alt, Zhang, Meng, Guo, & Schwer, 2013)].

16

Deaminating Cytosines creates Uracils, which can be processed into DSBs
Uracils produced by AID targeting can result in accurate repair, mutagenic repair,
or double-strand breaks. The base excision repair (BER) pathway is essential for
all of these functions and the mismatch repair (MMR) pathway primarily contributes
to mutagenic repair but can also take place in DSB formation –although the
mechanism is poorly characterized. Nucleotide excision repair (NER) does not play
a role in uracil processing. An overview of the BER process and DSB formation is
(1) AID deaminates cytosine to uracil, (2) UNG2 (the nuclear uracil-DNA
glycosylase) recognizes the uracil and removes it to create an abasic (AP for
apurinic, apyrimidinic) site, (3) apurinic/apyrimidinic endonuclease (APE) excises
the abasic residue to create a gap or nick in the single-strand. And (4) the presence
of nearby nicks on opposing strands creates a DSB.

Evidence for UNG as a component of the mutational process was first identified in
a bacterial system where deletion of UNG increased the mutational signature of
AID (Petersen-Mahrt, Harris, & Neuberger, 2002). Also, mutational signatures in
UNG-/- DT40 B cells changed to reflect repair by replication instead of dU removal
(Di Noia & Neuberger, 2002). In mice, UNG deficiency impaired SHM and CSR
(Rada, et al., 2002). A clinical phenotype of blocked CSR and reduced SHM in
several human patients was found to be a result of UNG mutations (Imai, et al.,
2003).
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Two different endonucleases have been implicated in removing the abasic site:
APE1 and APE2 (encoded by the genes Apex1 and Apex2, respectively). Apex1/-

mice and B cells are not viable. Heterozygotes (Apex1+/-) and Apex2-/- mice both

show a mild reduction in CSR, but the combined Apex1+/- and Apex2-/- mouse
shows a much stronger reduction (Guikema, et al., 2007). This would indicate that
both contribute to CSR, but in the CH12 cell line, homozygous deletion of Apex1
results in an 80% reduction in CSR, but Apex2 deletion has no effect (Masani,
Han, & Yu, 2013).

The mismatch repair (MMR) pathway also repairs U:G mismatches caused by AID.
Originally thought to only affect mutations resulting in SHM, MMR works in concert
with BER to generate DSBs [reviewed in (Pena-Diaz & Jiricny, 2012) and thus
facilitate CSR. The MMR pathway is made up of two complexes: MutSα (MSH2
and MSH6), which recognizes the mismatch, and MutLα (MLH1 and PMS2) which
signals downstream effectors. While MutSα promotes SHM and CSR (Chahwan,
et al., 2012), MutLα only functions in CSR. The specific MMR components that
reduce CSR are: Msh2 and Msh6 (Stavnezer & Schrader, 2006), (Martin, et al.,
2003), (Martomo, Yang, & Gearhart, 2004), (Li, et al., 2004), (Schrader, Vardo, &
Stavnezer, 2002), (Schrader, Edelmann, Kucherlapati, & Stavnezer, 1999); Exo1
(Bardwell, et al., 2004); PMS2 (Ehrenstein, Rada, Jones, Milstein, & Neuberger,
2001), and MLH1 (Chahwan, et al., 2012). It has been proposed that MMR
enhances the activity of BER in forming DSBs by processing more isolated nicks
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from the BER pathway into DSBs. If this is the case, a deficiency in MMR should
result in a reduction in CSR, but a combined deficiency in BER and MMR should
be equivalent to a deficiency in BER. In opposition to this, MSH6 shows no
reduction in CSR by itself, but a double knockout of MSH6 and UNG shows a
greater reduction in CSR than by UNG alone (Shen, Tanaka, Bozek, Nicolae, &
Storb, 2006). MMR must therefore be able to generate DSBs in CSR
independently of the BER pathway.

1.4 Synapsis

The synapsis or the close juxtaposition of DSBs created in activated switch regions
to facilitate end-joining of the DSBs, completes CSR. The resolution of DSBs by
productive CSR is different from the repair of a single pathological DSB or the
DSBs created by V(D)J recombination. In a pathological break, the two ends are
generated simultaneously and are in close proximity to each other. Similarly, the
RAG1/2 endonuclease complex brings the two RSSs into a synaptic complex
before they are cut. CSR does not initiate DSBs and translocate those breaks with
the same spatiotemporal precision. Topologically, CSR requires the efficient
translocation of a DSB in the Sμ (donor) region to a downstream accepter switch
region potentially over 100 kb distant. Timing-wise, the formation of DSBs is not
sufficient for and can be decoupled from synapsis. Internal deletions in Sμ are
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common in ex vivo stimulated B cells even if the cells have not yet switched (Alt,
Rosenberg, Casanova, Thomas, & Baltimore, 1982). These deletions without
downstream joining are termed intra-switch recombination reactions and the cells
retain their initial isotype expression. Several proteins have been implicated in the
process of synapsis. 53BP1-/- and H2AX-/- B cells have extreme CSR defects but
they do exhibit much higher rates of intra-switch recombination (Manis, et al.,
2004), (Ward, et al., 2004), (Reina-San-Martin, Chen, Nussenzweig, &
Nussenzweig, 2007). 53BP1 deficiency also decreases the joining of distal DSBs
more than breaks occurring in close proximity (Bothmer, et al., 2011).
Chromosomal conformation capture experiments have provided a model where
the 5’ and 3’ regions of the IgH locus, termed the Eμ (enhancer mu) and 3’RR (3’
Regulatory Region) come in three dimensional proximity to facilitate synapsis (Ju,
et al., 2007), (Kenter, et al., 2012), (Sellars, Reina-San-Martin, Kastner, & Chan,
2009), (Wuerffel, et al., 2007).

1.5 DSB Repair Pathways in CSR and Beyond

Repair of DSBs in CSR
Double strand breaks (DSBs) are perhaps the most critical type of DNA damage
for cells. A single DSB break in an essential gene is sufficient to induce cell death
or if left unrepaired elsewhere—induce apoptosis (Jackson, 2002). DSBs pose
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such a threat to genome integrity because in addition to the mutagenic nature of
DNA damage, the two free DNA ends in a DSB are no longer held together by
chromatin structure or complementary base pairing. Dissociation of the ends can
result in repair at inappropriate locations—i.e. a chromosomal translocation. Such
chromosomal rearrangements are frequently found in lymphomas, leukemias, and
solid tumors (Kuppers, 2005), (Nussenzweig & Nussenzweig, 2010), (Tsai &
Lieber, 2010), (Zhang, et al., 2010). Moreover, deficiencies in the DNA DSB
Response predispose to carcinogenesis (Jackson & Bartek, 2009), (Ciccia &
Elledge, 2010).

Sources of double strand breaks
DSBs can be classified according to the source and cause (Goodzari & Jeggo,
2013). Accidental or pathologic DSBs can result from exogenous factors (ionizing
radiation or radiomimetic compounds), but also endogenous sources (replication
fork collapse). DSBs can also be programmed as in chromosomal crossover in
meiotic recombination and are extensively utilized by the adaptive immune system
in jawed vertebrates (Cooper & Alder, 2006) in V(D)J recombination and CSR.

Recognition of the DSB and Repair Pathway Choice
Various DSBs require different modes of repair. The location of the break, phase
of the cell cycle, and origin of the break dictate repair choices. Although pathway
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choice begins as early as the primary detection of the break site, the irreversible
decision point is the amount of DNA resection. Classic Non-homologous end
joining (c-NHEJ) requires minimal end-resection, while homologous recombination
(HR) requires extensive end-resection. Two alternative pathways, alternative
NHEJ (a-NHEJ) and single-strand annealing (SSA), also require end-resection.

classic Non-homologous End-Joining (c-NHEJ)
Originally discovered in higher eukaryotes because yeast predominantly use HR,
c-NHEJ is the primary joining pathway for two-ended DSBs like those occurring
from irradiation, V(D)J recombination, and CSR (Goodzari & Jeggo, 2013). c-NHEJ
quickly

ligates

broken

DNA

to

suppress

chromosomal

translocations

(Difilippantonio, et al., 2000). Cells depend on c-NHEJ during the G1 phase
because it does not require a homologous template for repair. The fast kinetics
and template independence result in a slight loss of information—about 1-4 nt
resection at the break site.

Three steps comprise c-NHEJ repair of DSBs: (1) binding and stability, (2)
processing, and (3) ligation. First, the Ku70/Ku80 toroidal heterodimer (Ku) binds
to a DSB initiates c-NHEJ. Ku is sequence agnostic because it binds to the sugar
backbone of DNA and not the bases themselves (Walker, Corpina, & Goldberg,
2001). Ku recruits DNA-PKcs (DNA Protein Kinase catalytic subunit) in a DNA
dependent manner (Gottlieb & Jackson, 1993) to form the DNA-PK holoenzyme
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(Uematsu, et al., 2007). DNA-PK phosphorylates other NHEJ factors (Meek,
Douglas, Cui, Ding, & Lees-Miller, 2007) itself via autophosphorylation which is
essential for NHEJ (Chan & Lees-Miller, 1996), (Douglas, et al., 2007), (Cui, et al.,
2005), (Soubeyrand, Pope, Pakuts, & Hache, 2003). DNA-PK regulates the NHEJ
pathway by preventing extensive end-processing (along with other factors),
inactivating itself, and dissociating for the following steps (Neal & Meek, 2011).
The next steps and components in c-NHEJ are not inherently sequential; they are
flexible depending on the nature of the DNA damage and potential differences in
ligation method (Lieber, 2008), (Ma, et al., 2004), (Reynolds, et al., 2012). (2)
Ligation of a DSB requires 5’ phosphate and 3’-OH compatible ends. DSBs
generated from exogenous DNA damage or endogenous physiologic damage (as
in V(D)J or CSR do not have these structures. The DSB break must be processed
by nucleases and polymerases to facilitate ligation. These nucleases include:
Artemis, Werner (WRN), and. APLF. Artemis has 5’ endonuclease activity and
produces a blunt duplex end by nicking 5’ overhangs. It can also remove 5’—3’
ssDNA via it’s exonuclease activity. Finally, Artemis can remove 3’phosphoglycolate groups from DNA termini (Ma, Pannicke, Schwarz, & Lieber,
2002), (Povirk, Zhou, Zhou, Cowan, & Yannone, 2007). WRN binding to Ku and
the factor XRCC4 activates it’s 3’à5’ exonuclease activity (Cooper, et al., 2000),
(Kusumoto, et al., 2008), (Perry, et al., 2006). APLF is an endonuclease and can
also facilitate binding by resection 3’à5’ overhangs (Kanno, et al., 2007). If there
is sufficient complexity in the break, gaps in DNA can be filled in by the family X
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polymerases. Polymerase μ is template dependent and can polymerize across a
discontinuous strand using dNTP and rNTP (Nick McElhinny & Ramsden, 2004).
Polymerase λ is template independent and can remove deoxyribosephosphates
(Ramadan, Shevelev, Maga, & Hubscher, 2004), (Daley, Laan, Suresh, & Wilson,
2005). In V(D)J rearrangement in pro-B cells and developing T-cells, the terminal
deoxynucleotidyl transferase (TdT) add nucleotides between the gene segments
(Chang & Bollum, 1986). (3) Ligation of the processed DSBs occurs by Ligase IV
(Lig IV), the NHEJ specific ligase (Grawunder, et al., 1997), (Teo & SP, 1997),
(Wilson, Grawunder, & Lieber, 1997), XRCC4 stabilizes the interaction and also
serves as a platform for other factors with Ku (Li, et al., 1995). The protein XLF
(Cernunnos) (Ahnesorg, Smith, & Jackson, 2006), also promotes NHEJ by
repriming Lig IV and XRCC4 (Riballo, et al., 2009), and an XLF deficiency leads to
immunodeficiency and radiosensitivity (Menon & Povirk, 2017). XLF is technically
redundant in normal cell lines, and the persistence of NHEJ is due to paralogue of
XRCC4 and XLF (PAXX) (Kumar, Alt, & Frock, 2016), but in cells deficient for
ataxia telangiectasia-mutated (ATM) DSB response factor (a key component of the
DSB sensing and repair pathway) it is essential.

Homologous Recombination (HR)
Cells can use the sister chromatid as a template to repair DSBs. This process,
termed homologous recombination (HR), requires the cell to be in S/G2 phase,
after DNA duplication has occurred (Johnson & Jasin, 2000). The homologous
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chromosome in cells that have not replicated their DNA cannot be used for HR,
presumably due to sequence differences preventing heteroduplex formation. HR
primarily acts at the replication fork in fork restart and the repair of one-ended
DSBs (Adamo, et al., 2010), (Petermann & Helleday, 2010). The steps of HR are:
(1) 3’ single ended DNA (ssDNA) formation, (2) coating the ssDNA with RPA, (3)
displacement of RPA by RAD51 to form a nucleoprotein filament, (4) formation of
heteroduplex DNA and the Holliday junction (Bzymek, Thayer, Oh, Kleckner, &
Hunter, 2010), (5) branch migration and (6) resolution. Because HR is not utilized
in CSR, the following description of HR will focus on the characterization of HR as
a mutually exclusive pathway to NHEJ. While HR is functionally unavailable in G1,
it must outcompete NHEJ in S/G2 phases. This is accomplished in two ways: (1)
displacement of NHEJ promoting factors at the DSB, and (2) activation of HR
promoting factors. Because Ku shields DNA from exonucleases and is quickly
recruited to DSBs, Ku must be displaced to permit end resection. Ku displacement
has been proposed to occur by the ATM dependent phosphorylation of CtIP
displaces Ku in the S/G2 phase of the cycle to permit HR (Chanut, Britton, Coates,
Jackson, & Calsou, 2016) and the phosphorylation of Ku itself (Lee, et al., 2016).
Additionally, extensive resection of the DSB is facilitated by the activation of
helicases and nucleases: DNA2, BLM, WRN, CtIP, and Exo1 (Symington &
Gautier, 2011), (Sturzenegger, et al., 2014).
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Chromatin at the DSB: 53BP1 and Pathway Choice
In addition to factors that bind directly to DNA as a result of a DSB, the chromatin
surrounding the break is heavily modified to facilitate repair (Price & D'Andrea,
2013). First, the DSB is recognized by the MRN (MRE11-RAD50-NBS1) complex.
The NBS1 subunit recruits ATM (ataxia-telangiectasia mutated) (Lee & Paull,
2005), (You, Chahwan, Bailis, Hunter, & Russell, 2005), a serine/threonine kinase
member of the phosphatidylinositol-3-kinase-like kinase family (PIKK) (Maréchal
& Zou, 2013). The autophosphorylated and active form of ATM then
phosphorylates the histone variant H2Ax, becoming ϒH2AX. Mice lacking this
histone variant display the hallmarks of deficient DSB repair, including
radiosensitivity and immune deficiency (Celeste, et al., 2002). The MDC1
(mediator of damage checkpoint protein 1) protein then recognizes the ϒH2AX and
recruits more MRN and ATM to the chromatin (Stewart, Wang, Bignell, Taylor, &
Elledge, 2003), (Lou, et al., 2006). ATM and MDC1 then recruit the E3 ubiquitin
ligase RING finger 8 (RNF8), which also a second E3 ubiquitin ligase, RNF168.
Through a longer cascade, H2AK13 and H2AK15 are ubiquitinated which
recruits 53BP1 along with H4K20me1 andH4K20me2 (Panier & Boulton, 2014).
53BP1 blocks homologous recombination by inhibiting DNA end-resection
(Bunting, et al., 2010). It does so, by excluding another factor in HR, BRCA1
(Chapman, Sossick, Boulton, & Jackson, 2012), (Bouwman, et al., 2010).
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1.6 RIF1
RIF1 is an essential protein for NHEJ and CSR. It is the single, phosphodependent interactor and effector of 53BP1 to promote these processes. In this
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section I will cover the background of RIF1 as a protein and its known functions.

Oligmerization

Figure 4: Schematic of RIF1 protein from M. musculus
Diagram of RIF1 protein sequence highlight N-terminal HEAT/armadillo domains
(light blue) and C-terminal RxVF/Protein Phosphatase 1 (PP1) binding (red) and
BLM binding (purple) domains. C-terminal region necessary for oligomerization is
underlined.

Structure of RIF1
Murine RIF1 is a large (2462 aa) protein. The N-terminal half of the protein contains
several α-helical HEAT/Armadillo domain repeats which are required for IR
induced foci formation (Escribano-Díaz, et al., 2013). The C-terminal end contains
a FxVF domain that interacts with Protein Phosphatase 1 (PP1), Bloom syndrome
protein (BLM) and is required for oligomerization of RIF1 proteins (Silverman,
Takai, Buonomo, Eisenhaber, & De lange, 2004), (Sreesankar, Senthilkumar,
Bharathi, Mishra, & Mishra, 2012), (Xu, et al., 2010). The c-terminal domain, 3’ of
the RxVF domain is required to exclude BRCA1 G1 foci formation (Escribano-Díaz,
et al., 2013).
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Discovery and Function of RIF1
RIF1 was originally identified in yeast as an interactor of Rap1 (TERF2IP in
humans) to maintain telomere length (Nakamura, et al., 2006), (Marcand, Gilson,
& Shore, 1997) (Wotton & Shore, 1997). However, in vertebrates, RIF1 is a
diverged ortholog and not part of the telomeric complex, i.e. deficiency alone does
not result in telomere defects. Instead, vertebrate RIF1 affects DNA metabolism
(Buonomo S. , 2010), (Yamazaki, Hayano, & Masai, 2013). It is recruited to DNAdamage foci by irradiation (Silverman, Takai, Buonomo, Eisenhaber, & De lange,
2004), replication stress (Buonomo, Wu, Ferguson, & de Lange, 2009), and
telomere deprotection (Xu & Blackburn, 2004). Rif1 was also found to be important
in homology directed repair (Buonomo, Wu, Ferguson, & de Lange, 2009).
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Figure 5: Schematic of RIF1 Interaction with 53BP1
N-terminal ST/Q phosphorylation sites (red bands) on 53BP1 are necessary for
the interactions with PTIP and RIF1. The mechanism by which RIF1 interacts with
the phosphorylated form of 53BP1 is unknown. C-terminal domains of 53BP1 are
responsible for promoting binding to damaged chromatin (oligo), binding to
H3K20me2 (tudor), H2A-K15Ub (UDR), and the DNA repair in heterochromatin
(BRCT [BRCA1 C-terminal domain]) Note: BRCT is dispensable completely for
repair in CSR and mostly not needed for repair at dysfunctional telomeres. Figure
adapted from (Zimmerman, Lottersberger, Buonomo, Sfeir, & de Lange, 2013).

RIF1 and the Interaction with 53BP1
RIF1 had been found to interact with the p53-binding protein, 53BP1—a central
mediator of double strand break signaling and repair, by mass spectrometry (Huen,
Sy, & Chen, 2010), and was found to be dependent on 53BP1 for recruitment to
DSBs measured by formation of IR induced foci (Silverman, Takai, Buonomo,
Eisenhaber, & De lange, 2004). However, RIF1 emerged as the key DNA damage
dependent effector of 53BP1 with the discovery that it’s recruitment to DNA
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damage is dependent on ATM-mediated phosphorylation of S/TQ sites on 53BP1
(Di Virgilio, et al., 2013). Like 53BP1 (Manis, et al., 2004), (Ward, et al., 2004),
RIF1 deficiency resulted in a profound decrease in CSR (Escribano-Díaz, et al.,
2013), (Chapman, et al., 2013), (Di Virgilio, et al., 2013). The defect in CSR
resulted from increased 5’ end resection (Zimmerman, Lottersberger, Buonomo,
Sfeir, & de Lange, 2013), (Escribano-Díaz, et al., 2013), (Feng, Fong, Wang,
Wang, & Chen, 2013), (Chapman, et al., 2013), (Di Virgilio, et al., 2013). This was
consistent with 53BP1’s role in preventing 5’ end resection at DSBs, (Bothmer, et
al., 2010), (Bunting, et al., 2010), and was also mechanistically consistent
because the phosphomutant form of 53BP1, 53BP128A, could not prevent resection
at DSBs (Bothmer, et al., 2011) or telomeres (Lottersberger, Bothmer, Robbiani,
Nussenzweig, & de Lange, 2013).

Genome-wide, RIF1 functions epistatically to 53BP1. These include: decreased
cell survival (Silverman, Takai, Buonomo, Eisenhaber, & De lange, 2004), (Feng,
Fong, Wang, Wang, & Chen, 2013), (Chapman, et al., 2013); impaired DSB repair,
as measured by the increased persistence of γH2AX foci (Escribano-Díaz, et al.,
2013), (Chapman, et al., 2013); increased 5’à3’ end resection, as measured by
the accumulation of RPA a ssDNA binding protein essential for HDR, (Zimmerman,
Lottersberger, Buonomo, Sfeir, & de Lange, 2013), (Escribano-Díaz, et al., 2013),
(Feng, Fong, Wang, Wang, & Chen, 2013), (Chapman, et al., 2013), (Di Virgilio, et
al., 2013), and also the accumulation of RAD51, a downstream effector of RPA (Di
Virgilio, et al., 2013). MEF knockouts of 53BP1, RIF1, and both factors showed the
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same amount of increased 5’ end resection (Zimmerman, Lottersberger,
Buonomo, Sfeir, & de Lange, 2013). Additionally, phosphorylation at Ser345 of
ChK1, a marker of RPA-ssDNA on 5’ recessed DNA, was equal between all three
genetic backgrounds (Chapman, et al., 2013).

RIF1 differences from 53BP1
RIF1 recruitment to sites of DNA damage is more phosphorylation dependent than
53BP1 (Silverman, Takai, Buonomo, Eisenhaber, & De lange, 2004), (EscribanoDíaz, et al., 2013), (Chapman, et al., 2013). This is presumably due to 53BP1 being
recruited by histone marks as well as γH2AX (Kleiner, Verma, Molloy, Chait, &
Kapoor, 2015), while RIF1 is solely recruited by the phosphodependent interaction
with 53BP1. Dysfunctional telomeres were also found to join at a higher rate in
Rif1-/- cells (Zimmerman, Lottersberger, Buonomo, Sfeir, & de Lange, 2013). In
terms of cell survival, RIF1 was found to have a slightly reduced amount of cell
death (Chapman, et al., 2013), and in one study was only found to affect cell
survival in DT40 cells when they DNA damage was induced in G1 phase of the
cell cycle (Escribano-Díaz, et al., 2013).

While 53BP1-/- mice were found to be viable but radiosensitive and
immunodeficient (Ward, Minn, van Deursen, & Chen, 2003), (Morales, et al.,
2003), Rif1-/- mice were embryonic lethal (Buonomo, Wu, Ferguson, & de Lange,
2009). Interestingly, when such mice were outbred, they were viable, but at 50%
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of the expected mendelian ratio (Chapman, et al., 2013). RIF1 also displayed
phenotypes that were completely separate from 53BP1, specifically increased
sensitivity to replication stress and alteration in replication timing domains
(Buonomo, Wu, Ferguson, & de Lange, 2009), (Cornacchia, et al., 2012),
(Yamazaki, et al., 2012), (Xu, et al., 2010).

Remaining Questions about RIF1
Critical questions in the 53BP1-RIF1 DSB repair axis, are (1) how does RIF1
protect DNA DSBs from 5’ end resection, and (2) how does it interact with 53BP1.
Recently, studies have shown that mouse RIF1 was found to engage DNA
cruciform structures (Sukackaite, et al., 2014); bind ssDNA in vitro (Xu, et al.,
2010); and yeast RIF1 encases DNA ends (Mattarocci, et al., 2017) to promote
NHEJ and prevent telomere fusion. This is potentially relevant for vertebrate RIF1,
because RIF1 was found to mediate this function in the absence of the Rap-1
interacting domain. However, neither of those studies explain the interaction
between 53BP1 and RIF1. Specifically, because the interaction with 53BP1 is
phosphodependent, it would be expected to find DNA damage responsive,
phospho-interacting domains, like BRCT (Leung & Glover, 2011), in the RIF1
protein. This could point to a separate interactor mediating the phosphodependent
association of RIF1 and 53BP1.
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1.7 ZMYND8

ZMYND8 is the novel effector of CSR that was uncovered in this study. It has
previously been implicated in the DDR and suppression of transcription at DSBs.
In this section I will cover the background of ZMYND8 as a protein and it’s known
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Figure 6: Schematic of ZMYND8 protein from M. musculus
Diagram of Zmynd8 protein sequence highlighting N and C termini, total length,
and relevant domains (PHD Plant homeobox domain; BRD Bromodomain; PWWP
pro-trp-trp-pro; MYND myeloid-Nervy-DEAF-1). Domains are to scale with respect
to the length of the protein.

Zmynd8 (Zinc finger, MYND-type containing 8) protein [also called: RACK7,
PRKCBP1, and in very few cases SPIKAR] is encoded on mouse chromosome 2:
165784155-165899016 (mm10 build), negative strand. Multiple isoforms
potentially exist, ranging from 1094 aa to 1235 aa. For this study, any reconstituted
proteins used the 1235 aa isoform. The APPRIS principle isoform is 1199aa.
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Structure of ZMYND8 and Functional Domains
Relevant domains from N to C termini of ZMYND8 include:
PHD domain, located from 112-157 aa. Plant homeobox domain (PHD) finger is a
methyl reader domain. This PHD domain is a zinc finger—C3HC4 conserved motif
coordinates two Zinc ions (Sanchez & Zhou, 2011). Various PHD domain families
bind H3K4me3 or alternatively the unmethylated form H3K4me0.

BRD domain, located from 189-259 aa. Bromodomain is an acetylation-binding
module (Brand, et al., 2014). It targets acetylated lysines on histones. A conserved
arginine (N252) residue is crucial for Zmynd8-BRD function (Savitsky, et al., 2016).

PWWP domain, located from 301-351 aa. PWWP for (pro-trp-trp-pro) modules
contain a conserved aromatic cage for histone methyl-lysine recognition. They
synergistically bind histones and DNA. Zmynd8 has a conserved phenylalanine
and tryptophan residues that form this aromatic cage (Savitsky, et al., 2016).

MYND domain, located from 1064-1098 aa. MYND (myeloid-Nervy-DEAF-1) is a
C6HC zinc finger binding motif found in other nuclear proteins but does not bind
DNA (Gross & McGinnis, 1996). MYND domains are putative protein-protein
interaction domains in mammalian species (Liu, et al., 2007).
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Only 5 proteins in mice contain all three N-terminal domains (PHD-BRD-PWWP):
Zmynd11, BRPF1, BRPF3, BRD1, and ZMYND8 (Onodera, et al., 2012).

Discovery of ZMYND8
Zmynd8 was discovered as a binding partner of RACK1 (receptors for activated Ckinase) and originally designated PRKCBP1 (Fossey, et al., 2000). Soon after it
was identified as a cutaneous T-cell lymphoma associated antigen (Eichmuller, et
al., 2001). It was later defined as binding partner of FHOD1 using a yeast-twohybrid screen (Westendorf & Koka, 2004).

ZMYND8 and Transcription
Insight into Zmynd8’s function came with the discovery that it interacts with
RCOR2, a REST corepressor (Zeng, Kong, Li, & Mao, 2010). Localization via a
fused GAL4 (DNA binding domain) resulted in gene repression. Continuing with
the identification as a transcriptional silencer, knockdown of Zmynd8 was able to
reactive a silent GFP reporter in HeLa cells (Poleshko, et al., 2010). Multiple
complex partners were then identified including a transcriptional complex
containing ZNF687 and ZNF592 [also a hit in the I-DIRT in this study]. Interestingly,
Zmynd8 also bound to the POLR2A subunit of the RNA Polymerase II complex
(Malovannaya, et al., 2011). Although Zmynd8 is often referred to as a
transcriptional repressor, it is clear that it can upregulate and downregulate certain
genes, as (Li, et al., 2016) showed in the DU145 prostate cancer line (2,629 genes

35

upregulated, 2,551 downregulated). Knockout in a breast cancer cell line revealed
that not only were nearby genes upregulated, but enhancer RNAs (eRNA) were as
well (Shen, et al., 2016).

ZMYND8 and Cancer
Zmynd8 was more expressed in high-grade cervical intraepithelial neoplasia and
squamous cell carcinoma (Bierkens, et al., 2013). Although a highly referenced
paper for Zmynd8 entries online, its function as a driver in an acute myeloid
leukemia (AML) case is more likely due to the constitutive expression of the RELA
fused protein and the consequent activation of NFkB (Panagopoulos, et al., 2013).
However, this is noteworthy because it highlights that Zmynd8 is constitutively
expressed. In fact every tissue expresses Zmynd8

(Fossey, et al., 2000),

(Zmynd8, n.d.), (Gene: Zmynd8, n.d.). Zmynd8 was found to be upregulated in
certain cancer cell lines (DU145) and xenotransplant model in zebrafish. According
to one group, knockdown of Zmynd8 reduced Vegfa transcription and inhibited
cancer angiogenesis and progression (Kuroyanagi, et al., 2014). However, in
another group, the same cancer cell line and xenotransplant model found that
Zmynd8 knockdown increases invasiveness and metastasis (Li, et al., 2016).
Clinically, Zmynd8 was found to a prognostic marker for shorter survival of breast
cancer patients (Yu, et al., 2017), (Chen, et al., 2017).
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ZMYND8 Genomic Distribution
ZMYND8 was shown to primarily occupy promoter regions (Li, et al., 2016),
(Spruijt, et al., 2016); transcriptional start sites (Savitsky, et al., 2016); and
(super)enhancers (Spruijt, et al., 2016), (Savitsky, et al., 2016).

ZMYND8 and the Interaction with Epigenetic Marks
In accordance with the presence of PHD-BRD-PWWP N-terminal domains,
ZMYND8 interacts with epigenetic marks: H3.1K36me2, H4K16Ac (Adhikary, et
al., 2016); the PHD-Bromo domain reads H3K4me0/1-H3K14ac (Li, et al., 2016);
enhancers marked by H3K4me1, H3K27ac, DNase1, no HeK4me3 (Spruijt, et al.,
2016); actively transcribed genes marked by H3K4me3 and H3K9, K14 (at TSSs)
(Savitsky, et al., 2016); K27ac (Spruijt, et al., 2016); H3K4me1 and H3K27ac at
superenhancers and not H3K4me3 and H3K27ac (Shen, et al., 2016). These are
just a subset of the reported epigenetic correlations. Zmynd8 clearly interacts with
modified histones, but the exact combinatorial epigenetics remains to be
elucidated.

ZMYND8’s role in DNA Damage
The Miller group showed Zmynd8 functions represses transcription in response to
DNA damage (Gong, et al., 2015). Zmynd8 was shown to have H4-acetylation
dependent recruitment to sites of DNA damage by laser micro-irradiation. It also
confirmed the association of TRIM24 (Poleshko, et al., 2010) as a DNA damage
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dependent recruitment factor with Zmynd8. Interestingly, Zmynd8 knockdown
prevented S345p phosphorylation of Chk1. It should be noted that while S345p is
reported in some cases to be associated with ionizing radiation (IR) from X-ray
irradiation or

137Ce

γ-irradiation, it is primarily elicited by hydroxyurea (replication

stress) and UV irradiation (primarily NER, nucleotide excision repair) (Liu Q. ,
2001). Consistent with this difference, S345P is mediated by ATR (Jossé, et al.,
2014) and not ATM (Hickson, et al., 2005). Zmynd8 was shown to function in HDR
because it is required for repair in the DR-GFP assay (Pierce, Johnson,
Thompson, & Jasin, 1999), and it was required for Rad51 recruitment to sites of
endonuclease DSB damage (Iacovoni, et al., 2010). Furthermore, Zmynd8 was
only required for recruitment of the HDR factor Rad51 at endonuclease sites in
actively transcribed genes, while it was dispensable for the recruitment of NHEJ
factor XRCC4, which correspond with inactive genes (Aymard, et al., 2014).
Zmynd8 was further implicated in transcription-coupled DNA repair because
treatment with the RNA Pol II inhibitor, DRB (5,6-dichlorobenzimidazole riboside),
abolished the recruitment to sites of laser micro-irradiation. DRB inhibits
phosphorylation of the CTD (C-terminal domain) of Pol II (Dubois, Nguyen, Bellier,
& Bensaude, 1994), which prevents new Pol II from moving from the initiation
phase to the paused (S5-P) and elongation (S2-P) of transcription. Zmynd8 was
later shown to immunoprecipitate only with S5-P Pol II, and not S2-P Pol II
(Adhikary, et al., 2016).
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Zmynd8 was recruited to sites of endonucleases FokI, IsceI (Xia, et al., 2017) and
AsiSI DSBs, (Gong, et al., 2015), but not oxidative damage (Xia, et al., 2017).
Zmynd8 recruitment to DSBs in actively transcribing genes resulted in
demethylation of H3K4me3 (Gong, Clouaire, Aguirrebengoa, Legube, & Miller,
2017). Interestingly, recruitment to DSBs by ZFN endonucleases was mediated by
BRD2 and was excluded from the actual DSB site (+/- 0.5kb) and restricted to
flanking regions (Gursoy-Yuzugullu, Carman, & Price, 2017).

Remaining Questions about ZMYND8
A model has emerged where Zmynd8 is recruited to sites of DNA damage in
transcriptionally active regions and suppresses transcription by recruiting various
complexes (NuRD, Co-Rest, and Integrator) (Savitsky, et al., 2016). While
Zmynd8-/- mice are embryonic lethal (Zmynd8, n.d.), deletion in various cancer cell
lines seem to have mild effects, mostly increased growth and invasiveness (Li N. ,
2016), (Shen, et al., 2016). This is somewhat contradictory with clinical data as
higher Zmynd8 expression correlates with poor outcomes (Yu, 2017), (Chen,
2017). A fundamental question is what are the cellular consequences of Zmynd8
knockdown and how do those translate to the organism at large? Specifically, what
is the link between repressed transcription at transcriptionally active sites post
break and cell function?
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1.8 The IgH 3’ Regulatory Region (3’RR): The Prototypical SuperEnhancer

The 3’ RR is a ~28 kb region downstream of the Cα region, the most 3’ of the IgH
constant genes in mice. It is comprised of 4 enhancers, HS3a, HS1,2, HS3b, and
HS4a (in order extending 3’ from the Cα region). The entire region is required for
CSR (Vincent-Fabert, et al., 2010) and SHM (Rouaud, et al., 2013).

Discovery of the 3’ RR
The discovery of the 3’RR was preceded and prompted by characterization of the
5’ enhancer of the IgH constant region (Eμ). This enhancer is located between the
3’ JH segment and the 5’ CH region (Banerji, Olson, & Schaffner, 1983), (Gillies,
Morrison, Oi, & Tonegawa, 1983), (Neuberger, 1983). Eμ caused IgH genes to be
expressed in B cells when transfected. However, there was evidence of a second
control element for B cells. First, B cell lines that had deleted Eμ could still express
IgH (Eckhardt & Birshtein, 1985), (Zaller & Eckhardt, 1985). This transcriptional
redundancy could account for the expression of c-myc in c-myc:IgH translocations
in Burkitt lymphoma (human) and mouse and rat cancers with orthologous
translocations (Pettersson, Cook, Bruggemann, Wiliams, & Neuberger, 1990). The
requirement in secondary diversification reactions was confirmed in transgenic
models where deletion of Eμ caused V(D)J recombination reduction and reduced
B cell numbers, but B cells that were produced could undergo CSR and SHM
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(Perlot, Alt, Bassing, Suh, & Pinaud, 2005). The 3’ RR was identified first in mice
as HS 1,2 for two DNase I hypersensitive sites (Lieberson, Giannini, Birshtein, &
Eckhardt, 1991). Later other DNase I hypersensitive sites 3’ of Cα were identified
in mouse and humans and are reviewed in (Birshtein, 2014), (Pinaud, et al., 2011).

Function of the 3’RR
Early clues to the 3’RR function were found in low-producing plasmacytomas,
where the entire 3’ RR was spontaneously deleted (Michaelson, Giannini, &
Birshtein, 1995), (Gregor & Morrison, 1986). Later, endogenous deletions would
show reduced IgM in plasma cells, and that the 3’RR was required for CSR
(Vincent-Fabert, et al., 2010) and SHM (Rouaud, et al., 2013) but did not impair
V(D)J recombination (Rouaud, et al., 2012). Partial deletions of the IgH 3’RR give
heterogeneous results with respect to CSR. For example, deletion of Hs3b and
HS4 together eliminated class switching for everything except IgG1 (Pinaud, et al.,
2001). Other combinations of enhancer deletions or sequence inversions give
different results for CSR by isotype and SHM.

Chromatin Looping via the 3’RR
The mechanism of action for the 3’RR is still being dissected. However, interaction
of the 3’ RR with the IgH locus is required for function. This 3D interaction can be
measured

via

chromosome

conformation

capture

(3C)

and

expanded

technologies. Briefly, in 3C, cross-linking fixes chromatin in 3D space. The DNA is
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then digested and re-ligated in that 3D context. As a result, the anchor points of a
DNA loop may be re-ligated to each other. Primer pairs and PCR then amplify
those alternate linkages for detection. 3C found that in resting B cells loops form
between 3’RR and VDJ- Eμ but this loop does not exist in T cells (Wuerffel, et al.,
2007). Additionally, upon activation for CSR, the loop also includes a contact point
with the activated intronic enhancer. Furthermore, the degree of looping was
proportional to the amount of class switch derived from that enhancer (i.e. in LPS
+ IL-4 stimulation, Iϒ1 had the greatest looping, but in LPS only stimulation, Iϒ3 was
greater).

Histone Modifications due to 3’RR
The 3’RR and histone modifications have been implicated in targeting AID and
RNA pol II to s regions in CSR. H3K4me3 decorates the Sμ region constitutively,
but appears on downstream S regions after activation (Kuang, Luo, & Scharff,
2009). Deletion of the FACT complex in CH12 cells reduced H3K4me3 of switch
regions but did not reduce AID or GLT expression (Stanlie, Aida, Muramatsu,
Honjo, & Begum, 2010). Deletion of the Methyl transferase complex (Mixedlineage

leukemia

3

(MLL3/KMT2C)

–

MLL4/KMT2D

set1-like

lysine

methyltransferase complex) reduced CSR, slightly by 1.6 times in IgG1, and 2-fold
in IgG3 but did not decrease GLT of Sϒ1 or S ϒ3 (Starnes, et al., 2016). In humans,
Kabuki syndrome results from KMT2D mutations and presents in part as immune
deficiency due to hypogammaglobulinemia (Stagi, Gulino, Lapi, & Rigante, 2015).
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While the former modifications are dependent on activation for CSR but
independent of AID expression, H3ac appears to be AID dependent (Wang,
Whang, Wuerffel, & Kenter, 2006). Like H3K4me3, H3K9ac and H3K14ac
(together H3Kac) constitutively decorates the Sμ region, presumably due to
constant expression of GLT Sμ, but unlike H3K4me3, H3Kac also increases as a
result of activation (Wang, Wuerffel, Feldman, Khamlichi, & Kenter, 2009).
However, at downstream acceptor regions H3Kac is deposition correlates with
H3K4me3, that is to say it correlates with GLT specific transcription and is low or
undetectable prior to activation and GLT transcription. Interestingly, artificially
increasing H3Kac with histone deacetylase inhibitors (HDACs) led to higher CSR
independent of any dysregulation in AID (Wang, Wuerffel, Feldman, Khamlichi, &
Kenter, 2009).

Connecting back to the 3’RR, Saintamand and colleagues found that in 3’RR
deficient mice the histone modifications due to increased GLT and activation were
reduced at acceptor regions. Specifically, H3K4me3 is reduced at S acceptor
regions including, Sϒ1, S ϒ3, S ϒ2b, and Sε (Saintamand, et al., 2015). H3K9ac, Pol
II, and AID were also reduced at these regions. However, the donor region Sμ did
not show a reduction in H3K4m3, and the reduction in H3K9ac was minimally
reduced and at the 3’ end of the S region.
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Overall, the 3’RR is poorly conserved between species and aside from the welldefined function to promote CSR and SHM, the contribution and mechanism of
individual enhancers and intervening segments is still an open question.

Summary and Outlook

Class Switch Recombination (CSR) is a DNA recombination reaction that
diversifies the effector component of antibody responses. CSR is initiated by
activation-induced cytidine deaminase (AID), which produces nucleotide
mismatches in transcriptionally active immunoglobulin heavy chain (Igh) switch
donor and acceptor DNA. The process of CSR requires a functional DNA damage
response that facilitates ligation of the upstream donor and downstream acceptor
regions via NHEJ. 53BP1 and its effector RIF1 are critical to this process because
they inhibit end resection to promote NHEJ. However, the mechanism by which
RIF1 effects end-protection in CSR and binds to 53BP1 are still unknown.

In Chapter 2 I will describe experiments where we use proteomics to identify the
RIF1 interactome in actively switching B cells. In Chapter 3 I utilize the emerging
CRISPR-Cas9 system to orthogonally screen candidates from the proteomics
screen for functionality in CSR in the CH12 B cell lymphoma line. In Chapter 4 I
assess the newly identified candidate in DNA repair and CSR, ZMYND8, for effects
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on CSR prior to DSB break formation. In Chapter 5, I assess ZMYND8 for effects
in the DNA DSB repair process. In Chapter 6, I investigated the interaction
between ZMYND8 and transcription. In Chapter 7, I repeated the investigations
from Chapters 4-6 in a new conditional knockout mouse.
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Chapter 2: RIF1 Interactome in Activated B Cells

2.1 Validation of the Rif1FH/FH mouse for I-DIRT

We utilized an I-DIRT (Isotopic Differentiation of Interactions as Random
or Targeted) (Tacket, 2005) to investigate the RIF1 protein interactome in actively
switching primary B-cells. To increase the efficiency of RIF1 pull-down we utilized
a FLAG-tag (FT) fused RIF1 recombinant mouse strain. Before performing the
actual I-DIRT we needed to confirm that the knock in protein and cells behaved
similarly with respect to RIF1+/+ B-cells. To demonstrate this, we isolated
splenocytes from Rif1FH/FH mice (Cornacchia et al., 2012). These mice express a
knock-in RIF1 fused with 1xFLAG-2xHA N-terminal tags. The Rif1FH/FH mice
express RIF1 at physiologic levels in B-cells as demonstrated by Western blot
(Figure 2.1a). Additionally, the B-cells proliferate at comparable rates to Rif1+/+ Bcells when measured by CFSE staining (Figure 2.1b). Importantly, the Rif1FH/FH Bcells undergo CSR at similar rates to Rif1+/+ B-cells in ex vivo stimulating conditions
(Figure 2.1c LEFT representative FC graph, and RIGHT summary CSR data).

Note: figures below are adapted to/from the final publication: (Delgado-Benito, et
al., 2018)
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Figure 7: Rif1FH/FH B-cells express physiological levels of RIF1 protein and
support wild-type CSR levels.

(A) Western blot analysis of cell extracts from Rif1+/+ (WT) and Rif1FH/FH B-cells.
Triangles at the top of the graph indicate three-fold dilution. Negative control at the
left is Riff/f (flox) Cd19cre/+ mice loaded at dilution equivalent to highest Rif1+/+ (WT)
and Rif1FH/FH B-cells.
(B) Flow cytometry histograms measuring B-cell proliferation by CFSE dye dilution
96 h post stimulation with LPS, IL-4, and RP105.
(C) Left: Representative flow cytometry plots measure CSR to IgG1 under the
same conditions. Right: summary of three independent experiments (n = three
mice per genotype).
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2.2 Identification of RIF1 Interacting Proteins in Primary B-Cells

The I-DIRT approach in actively switching B cells was used to capture the RIF1
interactome with respect to CSR. We also irradiated the cells prior to collection to
enrich for Rif1 interactions in the DDR. Figure 2.2a shows a flow chart of the
experiment. The solubilized protein complexes were immunoprecipitated with FT
specific antibodies conjugated to magnetic beads. The complexes were natively
eluted with 3x FT peptides. The samples were digested with trypsin and run with
LC-MS/MS (liquid chromatography-tandem mass spectrometry) and the results
were analyzed with MaxQuant proteomics software (Cox & Mann, 2008).

We determined that a 96 h growth period in activating SILAC media was sufficient
for the majority incorporation of the heavy-labeled amino acids (Figure 2.2Bi, ii, iii
and Figure 2.2C). Each heavy and light peptide pair identified showed the 6
molecular weight increase and possessed an arginine or lysine at the C-terminus.
This confirms the incorporation of a single heavy-labeled arginine or lysine per
trypsin-digested peptide.

A full scale I-DIRT detected thousands of proteins (Figure 2.2D). The proteins were
sorted according to their abundance/enrichment ratio as determined by the
proportion of heavy peptides to total peptides (heavy and light) detected. The most
enriched and also most abundant protein detected was RIF1. The next protein was
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the phospho-dependent interactor of Rif1 (53BP1). Most of the proteins detected
displayed an abundance ratio characteristic of non-specific pull down (average of
0.49 ± 0.10 standard deviation). These points confirmed, respectively, that (a) Rif1FH was efficiently immunoprecipitated, (b) growth and immunoprecipitation
conditions were sufficient to identify 53BP1, a known DDR- dependent physiologic
interactor of Rif1, and (c) the heavy and light samples were combined at a 1:1 ratio.
Highly enriched co-immunoprecipitated proteins (i.e. abundance ratios > μ + σ)
included several transcription factors (Figure 2E), as well as many proteins
implicated in DDR (Chapter 3)
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Figure 8: Identification of RIF1 interacting proteins in primary B cells
undergoing CSR
(A) I-DIRT Schema in ex vivo cultures of splenocytes. Abbreviations: GA
(glutaraldehyde); LC-MS/MS (liquid chromatography-tandem mass spectrometry).
Rif1FH/FH and wild-type Rif1+/+ splenocytes were isolated and cultured in SILAC
media supplemented with isotopically heavy 13C Arginine and Lysine (Rif1FH/FH) or
light (normally abundant)

12C

Arginine and Lysine (Rif1+/+). The cells were grown

their respective media and activated with LPS, IL-4 and RP105 for 96 h. Cell
cultures were irradiated with 20 Gy, allowed to recover for 45 min, and flash frozen
as pellets in a liquid N2 bath. The pellets from heavy and light samples were added
in equal mass amounts and cryolysed. The cryolysed powder was extracted in
soluble form with sub-stoichiometric treatment with glutaraldehyde in order to
stabilize labile and/or transient interactions without alternative the native
composition of protein complexes (Subbotin and Chait, 2014). Protein complexes
were co-immunoisolated, trypsinized and analyzed via mass spectrometry.
(B) Mass spectrometry graph of heavy amino acid incorporation test. Primary B
cells were cultured for 96 hr in activating (LPS, IL-4, RP105) conditions in SILAC
media supplemented with

13C

labeled arginine and lysine. Representative mass

spectrometry graph of proteins(peptides) (B.i) ActG1 (VAPEEHPVLLTEAPLNPK)
(B.ii) Actb (ACFPSIVGR) (B.iii) Aldoa (IGEHTPSALAIMENANVLAR)
(C) Summary of three representative peptides and L à H shift. Abbreviations:
UniProtKB (UniProtein Knowledge Base entry); H M/Z (heavy molecular
weight/charge of peptide); L M/Z (light molecular weight/charge of peptide); Z
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(peptide charge); (H-L)*Z (difference in molecular weight/charge ratio multiplied by
charge to return the difference in MW between the heavy and light forms).
(D) Graph of proteins identified in the RIF1 I-DIRT. The proteins are arranged from
highest H/(H+L) (abundance ratio) to lowest. Error bars represent the standard
error of the abundance ratio mean for all peptides identified for each protein. Only
proteins with peptide counts ³ 4 and posterior error probabilities £ 10-4 are
included. The central line is the mean (0.49) and the σ is the standard deviation of
the distribution. Top: chart with proteins RIF1, 53BP1, and ZMYND8 identified.
Bottom: chart with regions defined as hits (red), non-specific interactors (purple),
and contaminants (blue) marked.
(E) Potential transcription related RIF1 interactors found among identified proteins
with abundance ratios > 2 σ above the mean.
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2.3 Confirmation of Zmynd8 and RIF1 Interaction

To validate the Zmynd8 association with RIF1 discovered in the I-DIRT, we
performed reciprocal co-immunoprecipitation experiments in primary B cells.
Zmynd8 efficiency co-immunoprecipitates with RIF1, and vice versa (figure 9a and
b). RIF1 involvement in DNA damage repair is dependent on ATM phosphorylating
53BP1. The phosphorylated 53BP1 then recruits RIF1 to the site of DNA breaks
(Chapman, et al., 2013), (Di Virgilio, et al., 2013), (Escribano-Díaz, et al., 2013),
(Feng, Fong, Wang, Wang, & Chen, 2013), (Zimmerman, Lottersberger,
Buonomo, Sfeir, & de Lange, 2013). To determine if the RIF1-Zmynd8 interaction
is also DNA damage-dependent, we co-immunoprecipitated each protein in the
presence or absence of IR-induced DNA damage, and the presence or absence
of an ATM inhibitor. While we confirmed that the association between RIF1 and
53BP1 is both DNA damage and ATM dependent (Figure 9a) (Di Virgilio, et al.,
2013), Zmynd8 co-precipitated with RIF1 and vice-versa regardless of DNA
damage or ATM activity (Figure 9a, Figure 9b). Therefore, Zmynd8 interacts with
RIF1 in vivo, independently of DNA damage.
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Figure 9: The interaction between ZMYND8 and RIF1 is DNA damageindependent.
(A-B) Western blot analysis of anti-FLAG(RIF1) (A), and anti- ZMYND8 (B)
immunoprecipitates from WT and Rif1FH/FH B lymphocytes either left untreated or
irradiated (10 gray (Gy), 45-min recovery) in the presence or absence of the ATM
kinase inhibitor KU55933 (ATMi). Data are representative of at least two
independent experiments for each co-immunoprecipitation.
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Chapter 3: RIF1 Interactors and CSR

3.1 CRISPR Cas9 Screen Design for CSR in CH12 cells

To validate the top hits in the I-DIRT we designed an orthogonal screen to assess
proteins for function in CSR. We utilized the newly functionalized S. pyogenes
CRISPR-Cas9 system (Ran, et al., 2013) in order to somatically target genes.
Specifically, the Cas9 nuclease cuts the gene at a site specified by the gRNA.
Repair by the error-prone NHEJ pathway leads to insertions and deletions (indels)
at the DSB. Indels are statistically likely to lead to frameshift mutations, which
create downstream premature stop codons, and hence delete the protein. We used
the CH12F3 (CH12) cell line, a B-cell lymphoma cell line derived from B10 H-2aH4bp/Wts mice (Kunimoto, Harriman, & Strober, 1988) which robustly switches from
IgM to IgA (Nakamura, et al., 1996) to measure defects in CSR caused by
CRISPR-Cas9-mediated deletion. The CH12 cell line has been extensively utilized
as a model system to explore CSR.

The CRISPR Cas9 screen in CH12 cells is similar to strategies from the Basu
(Pefanis, et al., 2014) and Martin (Le, et al., 2016), (Ramachandran, et al., 2016)
laboratories.
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We transiently expressed Cas9+gRNA with the px458 plasmid (Figure 10a) (Ran,
et al., 2013) via nucleofection into the CH12 cell line. Cas9 expression directly
correlates with GFP expression due to a 2A linker. GFP+ cells were sorted 2 days
post nucleofection and grown for 3 days in culture (Figure 10b). This time period
allowed for protein depletion as existing protein turned over and was not
replenished. Cells were then activated for 48 h and assessed for CSR to IgA by
flow cytometry.

gRNAs targeting the candidate genes were designed by accessing the APPRIS
principal isoform on ensembl. The first two gRNAs for each of the 5’ two terminal
exons were generated using the Zheng lab/MIT CRISPR design software (CRISPR
Design, n.d.). Exons unique to the APPRIS principal isoform were excluded. We
endeavored to create indels as close to the 5’ end of the gene as possible to
exclude the possibility of producing truncated but still function proteins.
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Figure 10: CRISPR Cas9 Screen Design to Assess CSR in CH12 Cells

(A) Plasmid map of pSpCas9(BB)-2A-GFP (PX458) deposited to Addgene
(plasmid # 48138) by Feng Zhang. A 2A linker allows linked translation of GFP and
the Cas9 protein.
(B) Experimental design of CRISPR-Cas9 CH12 cell screen. Log phase,
unactivated, cells are nucleofected at day 0. A percentage of cells successfully
acquired the plasmid. These GFP+ cells are detected and isolated by flow assisted
cytometric sorting (FACS). Cells are grown in culture for 3 days to allow recovery
from sorting, and for the preexisting protein to degrade after somatic deletion of
the target gene. At day 5, cells are activated for switching to IgA and measured by
flow cytometry at day 7.
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3.2 CRISPR Cas9 CSR Screen of I-DIRT Targets

The I-DIRT screen revealed many novel proteins in the B-cell RIF1 interactome.
167 proteins were identified with an abundance ratio greater than 1 standard
deviation above the mean in one or more of the I-DIRT replicates (pilot
experiments V1_10, V1_25, or V1_50 or full-scale experiments V2.1 or V2.2). We
used the CRISPR Cas9 system to orthogonally screen candidates that when
deleted showed, like RIF1, a defect in CSR.

Of the 167 statistically significant proteins, 17 (Fig 11a) were selected as initial
candidates for CSR testing. The 17 proteins were filtered through literature
searches identifying these candidates as possible components of the DDR, CSR,
and/or pathways also attributed to RIF1. Some candidates were selected for
further study if it had been identified in other screens, specifically proteomic or
CSR based (i.e. ZRANB2 from (Pavri, et al., 2010)).

For each candidate, 4 gRNAs for the first two earliest possible exons were
designed according to the criteria in Chapter 3.1. An example schematic for
Zmynd8 targeting is shown in figure 11b.

Each experiment included an empty (non-targeted) px458 vector as a negative
control and px458 with gRNAs against AID as a positive control. Example flow
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cytometry results can be seen in Figure 11b. For targets that showed a reduction
in CSR, Western Blot analyses were performed. An example for Zmynd8 is in
Figure 11c.

Figure 11d shows CSR normalized to empty vector for all the 17 candidates. Of
those tested, only Zmynd8 showed consistently down-regulated CSR. However,
not all gRNAs effectively deleted the target protein (as can be seen for Dynll1).
The positive hit, Zmynd8, was retested in 3 biologically independent repeats to
confirm a role in CSR (figure 11e). Bulk testing found that two different gRNAs
against different exons in Zmynd8 showed a 40-50% reduction in CSR.

It is noteworthy that gRNA against AID incompletely abrogated CSR (figure 11b
and all experiments as a positive CSR reduction control). This could either indicate
a heterogeneous population of nucleofected cells, i.e. not all cells that receive the
px458 plasmid successfully targeted the Cas9+gRNA complex, or it could
represent that indels created by gRNA targeting lead to in-frame deletions which
do not destroy the protein function. The two hypotheses can be distinguished by
isolating clones from a bulk population and screening for (un)successful protein
deletion and corresponding indels.
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Figure 11: CRISPR Cas9 CSR Screen of I-DIRT Targets
Table 1: I-DIRT statistically significant targets.
(A) Curated list of I-DIRT statistically significant targets. Protein listed in first
column, UniProtID identifier listed in second column, and the z-score averaged
across all I-DIRT experiments in third column. Proteins below in the offset are
positive controls, specifically RIF1, the bait in the I-DIRT and 53BP1, a phosphordependent interactor which was used to identify RIF1. * indicates hits from other
screens
(B) Scheme of Zmynd8 genomic locus and location of gRNAs used in this study
(scheme adapted from Ensembl ZMYND8-001 ENSMUST00000109269.7).
(C) CRISPR-Cas9-mediated targeting of Zmynd8 in bulk CH12 cell population
reduces CSR. Representative flow cytometry plots measuring CSR to IgA in
Cas9/gZmynd8-nucleofected CH12 cells. CRTL is cells nucleofected with empty
px458 plasmid. Cells were activated for 48h with aCD40, TGFb and IL-4. Numbers
indicate the percentage of IgA switched cells.
(D) Western blot analysis of whole cell extracts from CH12 cultures following
nucleofection with gRNAs against Zmynd8. Triangles indicate threefold dilution
(E) CSR Reduction Summary of I-DIRT candidates. Each point represents a
separate gRNA target for that protein. Proteins consistently showing decreased
CSR were tested with western blot analysis to confirm deletion of the protein and
labeled green. Proteins that did not show a downregulation in CSR were also
analyzed for western blot as a control and labeled red if the protein remained after
gRNA targeting (i.e. Dynll1).
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(F) Summary dot plot indicating CSR as a percentage of WT value (Ctrl: control,
either empty vector or gRNA selected not to bind in mouse genome) within the
same experiment. Each marker represents an independent experiment
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3.3 Deletion of Zmynd8 in clonal CH12 cell lines and validation
as CSR factor
Given that we saw higher than expected CSR levels in known key CSR
components (specifically AID, RIF1, and 53BP1 showing 10%, 50%, and 50%
normalized CSR, respectively chapter 3.2) with bulk CH12 nucleofection and
testing, we hypothesized that there might be heterogeneous targeting of proteins
by gRNAs. Therefore, we sought to isolate clones of Zmynd8 targeted
nucleofected CH12 cells to validate Zmynd8 in CSR.

Using the same methodology described in chapter 3.1, we single-cell sorted
nucleofected CH12 cells and generated gRNA targeted clones. Numerous clones
were characterized by Sanger sequencing of the gRNA target site, indel
identification resulting in frameshift mutations on both alleles, and confirmation of
protein deletion via western blot analysis. Each of the clones showed a greater
CSR defect (figure 12a) than the bulk population (10-30% residual CSR versus 5060% residual CSR (figure 11c and figure 11e). Western blot analysis of theses
clones (figure 12b) showed a more complete deletion of Zmynd8 than was seen in
bulk samples (figure 11D). Clones for AID, RIF1 and 53BP1 targeting also showed
residual CSR levels commensurate with expected CSR in total knockout mouse
models.

71

For further analysis, two clones were picked, termed Zmynd8_KO1 and
Zmynd8_KO2. Zmynd8 was deleted with gRNAs targeting the 4th and 5th exon
respectively. To confirm that Zmynd8 was responsible for CSR in these CH12 cell
lines, we retrovirally transduced KO cell lines with a vector containing the fulllength Zmynd8 gene (figure 12c). These reconstituted cell lines were activated for
CSR and switched at normal levels (figure 12d and 12e).

These experiments confirmed that Zmynd8 is required for efficient CSR in the
CH12 cell line.
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Figure 12: Deletion of Zmynd8 in clonal CH12 cell lines and validation as CSR
factor

(A) CSR defect in Zmynd8-/- clonal CH12 cell lines. Graph depicting CSR to IgA 48
hours after stimulation of WT, AID-/- and Zmynd8-/- CH12 clonal derivatives with
aCD40, TGFb and IL-4. Graph is representative of at least two independent
experiments. Ctrl: controls, including both WT and clones derived from targeting
CH12 with random sequences not present in the mouse genome. Significance was
calculated with Mann-Whitney test.
(B) Western blot analysis of Zmynd8 expression in Zmynd8_KO1 and
Zmynd8_KO2 with WT control.
(C) Plasmid map of retroviral vector containing full length Zmynd8. Zmynd8 was
cloned from the principal isoform as determined by Appris on ensemble. A 3x-FT
peptide was added to the C-terminus of the protein for downstream applications.
(D) Summary dot plot for four independent experiments measuring CSR to IgA 48
hours after activation of Zmynd8-/- CH12 cells lines reconstituted with empty vector
(EV) or full-length Zmynd8. CSR is expressed as a percentage of WT value
(uninfected WT cells) within the same experiment.
(E) Representative flow cytometry plot of reconstitution and activation experiment.
WT, KO1 and KO2 cells lines were left un-reconstituted or reconstituted with empty
retroviral vector or Zmynd8 full length. Cells were activated for 48 h with IL-4, TGFβ, and CD40. Cells were gated for live singlets and on GFP-/+ [unreconstituted/reconstituted].
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3.4 Zmynd8 validation as a CSR factor in Primary B cells

Many of the 17 I-DIRT candidates tested for CSR had no available knock out or
conditional knock out mouse strains. Because of this we set out to utilize the
recently constructed Cas9-2A-GFP knock in mice generated by the Zhang lab
(Platt, et al., 2014) to somatically delete gRNAs in primary B-cells. In doing so we
could confirm results detected in the CH12 cell line and continue experiments in
primary B-cells.

The knock in mice contained a P2A linker to co-express eGFP with hSpCas9 from
the Rosa26 locus (Figure 13a). Because Cas9 was already present in B-cells (as
determined by eGFP detection in flow cytometry) only the gRNA would need to be
delivered to the splenocytes. This allowed us to design a retroviral vector dr17003 (figure 13b) under the packaging size limit (~10-11kb) required to effectively
spinoculate B cells. Ideally the gRNA would be delivered to B-cells prior to
activation, allowing time for (1) production of the retroviral transduced gRNA, and
(2) somatic targeting of the desired locus and (3) turnover of the pre-existing
protein in the cell. However, normally cultured ex vivo splenocytes die without
cytokine stimulation. To avoid this, cells were cultured ex vivo with the mitogen
RP105 to stimulate cell proliferation without activation of CSR. An experimental
schema can be seen in (figure 13c). Briefly, splenocytes were isolated and grown
in culture with RP105 for 1 day, spinoculated the next day, activated 48 h later,
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and measure for CSR at 72 h post activation. Representative flow cytometry plots
(figure 13d) show minimal difference in CSR between in Rosa26Cas9/+ and WT
primary B-cells, greatly reduced switching in cells with gRNA targeted to AID, and
about a 50% reduction in CSR in cells with gRNA targeted to Zmynd8. Three
independent biological repeats (figure 13e) show a statistically significant
decrease in gRNA against AID and also in gRNA against Zmynd8 (2 different
gRNAs per gene). This reduction shows that Zmynd8 also functions in CSR in
primary B-cells as well as the CH12 cell line.
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Figure 13: Zmynd8 validation as a CSR factor in Primary B-cells

(A) Knock-in schema of Cas9-2A-eGFP at the Rosa26 locus adapted from (Platt,
et al., 2014). The lox-stop-lox (LSL) section was excised in generating the mice.
The hspCas9 protein is constitutively expressed from the Rosa26 locus and can
be detected due to the coexpression of eGFP.
(B) Retroviral vector to deliver gRNA to Cas9 expressing B-cells. This vector was
constructed based on a pMX backbone and incorporates a tandem BbsI cloning
site for gRNA oligos, driven by a hU6 promoter.
(C) Experimental Outline for gRNA targeting in Rosa26Cas9/+ primary B-cells.
Splenocytes are harvested and grown ex vivo for 1 day with RP105 to stimulation
proliferation. Cells are then spinoculated with a retrovirus containing the gRNA of
interest and a BFP+ marker. After 2 days, the cells are activated by adding IL4 and
LPS. At 72 h post activation cells are measured for CSR by staining for IgG1.
(D) Representative flow cytometry plot of gRNA targeting in Rosa26Cas9/+ primary
B-cells. Cells were filtered for live singlets, and BFP+ indicated successful
transduction with the retroviral vector. gRNAs were identical to those used in CSR
experiments on CH12 cells. All B-cells displayed GFP+ to confirm Rosa26Cas9/+
genotype. Splenocytes were isolated and cultured in RP105 supplemented media
for 24hrs prior to spinoculation with gRNA retroviruses. Cells were culture for
another 2 days and then stimulated for CSR with RP105, IL-4, and LPS.
Measurements were taken at 72hrs post stimulation. And EF1a promoter drives
expression of mBFP2 to allow detection by flow cytometry.
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(E) Dot plot summary of retorivrial gRNA targeting in Rosa26Cas9/+ primary B-cells.
Values are normalized to switching in empty gRNA vector for that experiment.
Three independent biological replicates were conducted. * indicates significance
as determine by a Mann-Whitney test.
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Chapter 4: ZMYND8 in CSR: Pre-Break

AID is the apex initiator of CSR. It is primarily regulated transcriptionally (Zan &
Casali, 2013). It is necessary for CSR in B-cells (Muramatsu, et al., 2000) and
ectopic expression can even induce CSR in non-B cells (Okazaki, Kinoshita,
Muramatsu, Yoshikawa, & Honjo, 2002). AID is a haploinsufficient gene as
reductions in AID transcription levels decrease CSR (Sernandez, de Yebenes,
Dorsett, & Ramiro, 2008), (Takizawa, et al., 2008). Additionally, micro-RNAs,
specifically miR-155 (An, et al., 2010), regulate AID post-transcriptionally (Grace,
et al., 2008). Additionally, CSR requires expression of sterile non-coding (germline)
transcripts from the intronic promoters preceding the constant regions (Stavnezer,
Guikema, & Schrader, 2008). Lastly, CSR requires cell proliferation (An, et al.,
2010), (Stavnezer, Guikema, & Schrader, 2008). A defect in any of these
processes would result in impaired CSR. As such we sought to confirm that
Zmynd8 deletion did not result in absent or reduced AID or GLT transcripts or
defective proliferation.

4.1 Zmynd8 and AID expression

We chose to measure AID RNA transcripts via RT-qPCR. RNA from CH12 cells
was collected at 48 h post induction and measured. Transcripts were normalized
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to GAPDH and to AID levels in WT CH12 cells. There was no reduction in AID
transcripts according to RT-qPCR (figure 14a)
However, Zmynd8 could potentially be regulating AID post-translationally (Basu,
Franklin, & Alt, 2009). To test this we performed a western blot analysis of whole
cell extract of nucleofected bulk CH12 cells (figure 14b). We did not see any
reduction in AID protein levels for four different gRNAs against Zmynd8 tested.

Lastly, Zmynd8 could potentially be regulating AID function by affecting (1)
localization (i.e. altering the distribution between cytoplasmic AID and nuclear AID)
(Hasler, Rada, & Neuberger, 2011), (Wang, et al., 2016); (2) stability and
degradation (Uchimura, Barton, Rada, & Neuberger, 2011), (Aoufouchi, et al.,
2008); (3) AID phosphorylation (Basu, et al., 2005), (McBride, et al., 2006); and (4)
general AID activity (Li, et al., 2012). We chose not to pursue those investigations,
respectively, because (1) Zmynd8 has not been shown as an AID binding factor or
vice-versa, (2) Zmynd8 has not shown to function in protein degradation or
stability, and (3) Zmynd8 has no putative kinase type activity or (4) iron
sequestering capability. If Zmynd8 were altering CSR through one of these four
mechanisms, we would expect it to do so via a secondary mediator.
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Figure 14: Zmynd8 does not alter AID levels

(A) Zmynd8 does not lower AID expression. WT, Zmynd8 KO-1, Zmynd8 KO-2,
clones were activated for 48 h with IL-4, TGF- β, and CD40. RNA was isolated,
and RT-qPCR performed. A WT unactivated sample was included as a point of
reference. WT was assigned an arbitrary value of 1.0. There was no difference
between WT, KO-1 and KO-2 using the Mann Whitney U test to test for significance
(error bars represent SD).
(B) Western blot analysis of whole cell extract of nucleofected bulk cells with gRNA
targets. Cells were sorted on successful nucleofection (GFP+)but not clonally
isolated, except for the first two columns which are un-nucleofected controls. All
cells except for column 2 (WT no ACT) were activated with IL-4, TGF- β, and CD40
and harvested at 48h.
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4.2 ZMYND8 and Germline Transcription

Germline transcription (GLT) is necessary for CSR. To briefly summarize
(Matthews, Zheng, Di Menna, & Chaudhuri, 2014) and (Yewdell & Chaudhuri,
2017), unlike AID expression, GLTs are specific for each isotype. GLT through
switch μ is constitutive while downstream acceptor GLT, in the case of CH12
switching from IgM to IgA GLTα is inducible upon activation. GLTs facilitate locus
accessibility and AID targeting to the switch regions in the IgH so AID can initiate
DSBs that precede CSR. We wanted to investigate if a decrease in GLT accounted
for the CSR defect in Zmynd8 KO CH12 cells.

We chose to measure the relevant germline transcripts in CH12 cells, GLTμ and
GLTα, via RT-qPCR. RNA from CH12 cells was collected at 48 h post induction
and measured. Transcripts were normalized to GAPDH and to GLT levels in WT
CH12 cells. There was no reduction in GLTμ or GLTα transcripts according to RTqPCR (figure 15a, figure 15b).
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Figure 15: Zmynd8 deletion in CH12 cell line does not reduce GLT
(A) Zmynd8 deletion does not reduce GLTμ expression. WT, Zmynd8 KO-1,
Zmynd8 KO-2, clones were activated for 48 h with IL-4, TGF- β, and CD40. RNA
was isolated, and RT-qPCR performed. A WT unactivated sample was included
as a point of reference. WT was assigned an arbitrary value of 1.0. There was no
difference between WT, KO-1 and KO-2 using the Mann Whitney U test to test for
significance (error bars represent SD). Data are representative of two biologically
independent experiments.
(B) Zmynd8 deletion does not reduce GLTα expression. WT, Zmynd8 KO-1,
Zmynd8 KO-2, clones were activated for 48 h with IL-4, TGF- β, and CD40. RNA
was isolated, and RT-qPCR performed. A WT unactivated sample was included
as a point of reference. WT was assigned an arbitrary value of 1.0. There was no
difference between WT, KO-1 and KO-2 using the Mann Whitney U test to test for
significance (error bars represent SD). Data are representative of two biologically
independent experiments.
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4.3 Zmynd8 and Cell Proliferation

Cell proliferation is necessary for CSR (Reviewed in (Stavnezer, Guikema, &
Schrader, 2008)). We sought to investigate if reduced cell proliferation or altered
cell cycle distribution contributed to the reduction in CSR. By measuring cell
divisions via CFSE (5-(and -6)-carboxyfluorescein diacetate succinimidyl ester)
dilution, we wanted to observe if CH12 Zmynd8 KO cell lines exhibited reduced
proliferation.

CFSE staining is a well-established protocol to monitor lymphocyte division (Lyons
& Parish, 1994), (Quah, Warren, & Parish, 2007). Treatment with CFSE, or tradenamed fluorescent variants CellTrace, covalently labels intracellular amines, and
each cell division halves the signal intensity as molecules are divided between
daughter cells. We CFSE labeled un-reconstituted, reconstituted with empty
vector, and reconstituted with full-length Zmynd8 CH12 clones, activated the cells
and measured dilution differences at 48hr.

Unfortunately, CH12 cells could not resolve individual cell division peaks, and the
population of cells move homogeneous as a single peak. Noting this sensitivity
limitation, we observed no differences between non-reconstituted, empty
reconstituted, and Zmynd8 reconstituted WT cells (figure 16a). In the Zmynd8 KO
cell lines KO-1 and KO-2 we also observed no differences (figure 16b), (figure
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16c). While this does not exclude the possibility of subtle cell division differences,
we could not observe any gross population level differences in cell proliferation
that could account for CSR deficiency.
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Figure 16: Z8 Deficiency does not lead to reduced proliferation in CH12 cells

All cultures were reconstituted with nothing/mock, empty vector, or full length
Zmynd8 vector as indicated. After selection with puromycin and recovery, and
immediately prior to activation, cells were stained with CellTrace Violet (CFSE),
and measured by flow cytometry. Cells were then activated to switch with IL-4,
TGF- β, and CD40. 48 h post activation cells were measured to assess for class
switching and CellTrace dilution.
(A) Combined histogram of WT CH12 cells at 0 h and 48 h as indicated.
(B) Combined histogram of Zmynd8 KO-1 CH12 cells at 0 h and 48 h as indicated.
(C) Combined histogram of Zmynd8 KO-2 CH12 cells at 0 h and 48 h as indicated.
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Chapter 5: ZMYND8 in CSR: Post-Break

The DNA damage response to DSBs is highly coordinated and involves
successive, hierarchical localization of various factors (Panier & Boulton, 2014),
(Zimmermann & de Lange, 2014). Specifically, proteins ϒH2AX, 53BP1 and RIF1
organize sequentially to form foci at the chromatin flanking DSBs to facilitate repair
(Polo & Jackson, 2011). Such foci can be visualized with immunofluorescence
microscopy. Experimentally, cells are exposed to ionizing radiation and the
formation of these irradiation-induced foci (IRIF) is measured. DSBs are necessary
for CSR. As such, defects in the detection, signaling cascade, or repair of these
breaks can impede CSR (Methot & Di Noia, 2017).

Because the DSB repair processes are common both to AID induced breaks and
non-physiologic damage like ionizing radiation, we can investigate IRIFs and DSB
repair in one cell type and apply those findings to DSB repair in CSR.

We set out to explore the formation via IRIF and hierarchy of Zmynd8 and known
DSB repair factors in immortalized mouse embryonic fibroblasts (iMEFs). On a
technical note, iMEFs are typically used for such investigations instead of B-cells
because adherent cells can be visualized by the confocal microscopy necessary
for IRIF detection.
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5.1 DNA Damage Response Signaling and Zmynd8
First, Zmynd8 iMEF cell lines needed to be generated. Using the same transient
expression of Cas9 and relevant gRNAs used to make the KO CH12 cell lines, we
nucleofected iMEFs with the same Cas9+gRNA plasmids. iMEF clonal derivatives
KO-1, KO-2, KO-3 showed loss of the Zmynd8 protein by western blot analysis
(figure 17a). Consistent with the loss of protein in the blots, immunofluorescence
also showed a loss of Zmynd8 (Figure 17b). It is also noteworthy that Zmynd8 is
restricted to the nucleus of iMEFs. However, treatment with ionizing radiation did
not lead to detectable Zmynd8 IRIFs (Figure 17c). Unlike ϒH2AX, 53BP1 and RIF1
(Figures 17d, e, f) Zmynd8 does not appear to form IRIF post-treatment with
ionizing radiation. This does not exclude Zmynd8 from the DDR process, but it may
mean that Zmynd8 does not concentrate at breaks in sufficient concentration to be
visible by IF (many NHEJ components, i.e. Ku70 and Ku80, are in this category
(Britton, Coates, & Jackson, 2013)). Despite the inability to form foci under the
specified irradiation treatment, we could still assess if ϒH2AX, 53BP1 and RIF1
IRIF are dependent on Zmynd8. Foci for these three factors showed no decrease
in formation Figures 17d, e, f), which indicates that Zmynd8 does not function
upstream of ϒH2AX, 53BP1 or RIF1 in DSB repair.
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Figure 17: IRIF formation in Zmynd8 Deficient MEFs

(A) Western blot analysis of immortalized mouse embryonic fibroblasts (iMEF)
clonal cells lines. Ctrl iMEFs cell lines include a WT clonal derivative (WTc) and
two clones generated by targeting iMEFs cells with a random sequence not
present in the mouse genome (R-1 and R-2)
(B) Immunofluorescent staining of Zmynd8-/- and WT iMEFs. Zmynd8 staining is
shown in red, and 4',6-diamidino-2-phenylindole (DAPI) counterstains DNA in the
nucleus blue. Cells were not treated with irradiation.
(C-F) Immunofluorescent staining of Zmynd8-/- and WT iMEFs with 10 Gy
irradiation and allowed to recover for 90 min and 6 h.

97

A

B

C

98

D

Untreated

90 min

6h

DAPI

γH2AX

DAPI

γH2AX

DAPI

53BP1

DAPI

53BP1

DAPI

53BP1

DAPI

Rif1

DAPI

Rif1

DAPI

Rif1

DAPI

Zmynd8-/-

WT

γH2AX

Zmynd8-/-

WT

E

Zmynd8-/-

WT

F

99

5.2 Genomic Instability and Zmynd8

Chapter 5.1 detailed that Zmynd8 does not form IRIF and does not alter IRIF
formation in the ϒH2AX, 53BP1 and RIF1 axis in repair of DSBs. This does not
exclude Zmynd8 participating in the DNA repair process post RIF1 foci formation
or in another branch of DNA repair (Ciccia & Elledge, 2010).

A deficiency in DNA repair would contribute to genomic instability in the cell.
Alterations of basic cellular processes, i.e. the ability to proliferate and the
frequency of cell death, are outcomes of genomic instability. To broadly determine
if Zmynd8 plays a role in DNA repair we chose to assess cell survival and
proliferation in Zmynd8 deficient cells.

Genomic instability can be detected by a clonogenic survival assay (Franken,
Rodermond, Stap, Haveman, & van Bree, 2006). This is an in vitro assay to
determine the rate of cell death and proliferation capabilities in surviving cells after
treatment with irradiation or other radiomimetic agents. iMEFs were seeded,
irradiated, grown and then stained with crystal violet to visualize cell growth. The
presence of Zmynd8 had no impact on clonogenic survival (representative data,
figure 18a; summary data, figure 18b). Cell counting proliferation assays showed
that Zmynd8 also does not function in survival and post irradiative growth in CH12
cells (figure 18c). Confirming this point, we showed that BrdU incorporation, a well-
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established technique for detecting cell growth through the uptake of the BrdU
nucleotide analog in replicating DNA (Porstmann, Ternynck, & Avrameas, 1985),
(Magaud, et al., 1989), and (Huong, et al., 1991) is not altered by the Zmynd8
deficiency (figure 18d).

It is possible, that Zmynd8’s effect on cell survival may only manifest under
particular conditions, like BRCA deficiency and PARP inhibition (Helleday, 2011).
To test this we performed the clonogenic survival assay with PARP treatment
instead of ionizing irradiation. Zmynd8-/- iMEF cell lines showed no survival defect
(figure 18e). Lastly, Zmynd8-/- iMEFs did not show an increase in chromosomal
aberrations as visualized with metaphase spreading (18f).
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Figure 18: Zmynd8 deficiency does not lead to impaired cell survival,
growth or genomic instability

(A) Representative image of clonogenic survival assay. iMEFs of the indicated
genotypes were reconstituted with empty vector or full length Zmynd8 as listed,
seeded for 24hr, irradiated as marked, and stained after 10 days of growth with
crystal violet.
(B) Summary data of clonogenic survival assay. Error bars represent the mean
from triplicate plates per condition. Data are representative of two independent
experiments
(C) Growth curves of WT and Zmynd8-/- CH12 cells after irradiation. Measurements
were taken in triplicate.
(D) Cell cycle analysis of irradiated Zmynd8-/- CH12 lines as measured by BrdU
incorporation.
(E) Clonogenic survival assay of Zmynd8-/- iMEF clones following PARPi
treatment. Error bars represent the mean from triplicate plates per condition. Data
are representative of two independent experiments.
(F) Analysis of genomic instability in metaphases from PARPi-treated Zmynd8-/iMEFs (n >= 42 metaphases analyzed per genotype).
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5.3 DNA End Protection and CSR

CSR depends on NHEJ (Kotnis, Du, Liu, Popov, & Pan-Hammarström, 2009) and
to a lesser extent MMEJ (Sfeir & Symington, 2015), which can serve as a backup
pathway. RIF1 facilitates CSR by preventing end-resection at DSBs, thereby
promoting NHEJ instead of HR (Symington, 2014). To assess whether Zmynd8
impacts CSR by altering end-resection, we set out to directly measure the degree
of DNA end-resection at DSBs in Zmynd8-/- CH12 cells.

We

created

an

assay to measure end-resection

in intrachromosomal

translocations directed by Cas9 (figure 19a). Two gRNAs direct Cas9 to create
DSBs at the Rosa26 locus. Cells that have successfully cut at both targets are
screened for the smaller, recombined locus by PCR. Sanger sequencing can then
detect unilateral end resection at each DSB site. This schema has the advantage
of being analogous to the intrachromosomal recombination in CSR.

Zmynd8-/- CH12 cells showed no increase in end resection compared to WT cells
(figure 19b). Additionally, the KO’s showed statistically less resection compared to
the 53BP1-/- control (Bothmer, et al., 2010). There was no difference between the
KO cell lines.
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We adapted an AID-independent, Cas9 mediated, CSR assay (Le, et al., 2016), to
assess whether Zmynd8 could affect CSR post DSB induction at the IgH locus
(figure 19c). In the assay, CH12 cells are nucleofected with a Cas9 plasmid
carrying two-gRNAs, which target 5’ Sμ and 3’ Sα. By measuring CSR, we can
investigate the cell’s ability to synapse the distal DSBs and to ligate them. We
found that Zmynd8-/- CH12 cells showed no difference in CSR in the gRNA-CSR
assay (figure 19d). Representative flow cytometry plots show that there is no CSR
in the absence of the specific gRNAs (figure 19e). There was a reduction in CSR
in Lig4-/- CH12 cells, which leads to impaired DSB ligation, and 53BP1
cells, which impairs synapsis of distal DSBs.
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-/-

CH12

Figure 19: Zmynd8 does not affect end-resection or Cas9 mediated CSR in
CH12 cells
(A) Schematic representation of the end resection assay
(B) Dot plot showing resection in sequences from joining products of two CRISPRCas9-induced DSBs at the ROSA26 locus in two Zmynd8-/- CH12 cell lines (KO-1
and KO-2). Each dot represents one junction product. Number of junctions
analyzed per genotype is indicated below. p values were calculated with MannWhitney test. n.s.: not significant.
(C) Schematic representation of CRISPR-Cas9-induced CSR assay
(D) Summary dot plot for three independent experiments in the gRNA-CSR assay.
Significant reductions are indicated.
(E) Representative flow cytometry plots measuring CSR to IgA after
electroporation of inactivated CH12 cells lines of the indicated genotypes with WT
Cas9 and gRNAs against Random or Sa and Sµ sequences
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Chapter 6: ZMYND8 and Transcription

Because Zmynd8 does not affect CSR in CH12 cells by regulating AID expression,
germline transcription, cell proliferation, or DNA repair, and in other contexts
Zmynd8 has been reported to affect transcription (Shen, et al., 2016), (Gong, et
al., 2015), (Li, et al., 2016), (Gong, Clouaire, Aguirrebengoa, Legube, & Miller,
2017), (Spruijt, et al., 2016) we chose to investigate how Zmynd8 deficiency
influences the general transcriptional landscape in CH12 cells.

6.1 Zmynd8 and the Transcriptional Landscape

To characterize the transcriptional differences due to Zmynd8, we performed rRNA
depleted RNA-seq. This method allows us to measure ncRNAs and any pre-polyA
processed RNA as well as mature mRNAs (O'Neil, Glowatz, & Schlumpberger,
2013).

We compared CH12 Zmynd8-KO1 (KO1), Zmynd8-KO2 (KO2), WT, and clonally
derived WT (WTc) cells under unactivated and activated conditions. Dendrogram
hierarchical clustering of the samples (figure 20a) showed that WT and WTc
clustered separated from KO-1 and KO-2. This indicates that the KO clones are
transcriptionally similar, and the WTc is representative of the WT bulk. The next
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clustering level was based on activation or nonactivation conditions. This shows
that stimulation for CSR causes greater transcriptional changes than the presence
of Zmynd8. We could also see that samples clustered well together using principal
component analysis according to Zmynd8 presence, and activation status (figure
20b). We checked if 64 known CSR factors were transcriptionally affected by
Zmynd8 deletion in CH12 cells (figure 20c), but found no differences.
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Figure 20: Zmynd8 and Transcription in CH12 Cells
(A-B) Dendrogram (A) and Principal Component Analysis (B) for WT CH12 cells
(bulk and one clonal derivative, WTc) and two Zmynd8-/- cell lines (KO1 and KO2)
under either unactivated or activated conditions (prefix “a” indicates stimulation for
48h with aCD40, TGFb and IL-4). RNA-Seq analysis was performed on three
biological replicates per condition. Prepared sample libraries were run in duplicate
across two sequencing lanes.
(C) Scatterplot for gene expression of known CSR factors in activated WT CH12
and Zmynd8-/- samples. Pairwise comparisons between WT and Zmynd8-/- cell
lines are represented as different shapes, while CSR factors are denoted by color.
Linear regression line shown in blue; identity line shown in grey.
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6.2 Zmynd8 and AID Targeting of Switch Regions

CSR requires efficient AID targeting of the switch regions preceding the Cµ and
Cx (downstream heavy chain) region. AID preferentially deaminates at the switch
regions, due to the sequence specificity of AID for RGYW motifs, the high
concentrations of these motifs in the switch regions, protein-AID partner
interactions, and transcriptional activity (Chandra, Bortnick, & Murre, 2015). Given
that Zmynd8 deficiency does not alter CSR by lowering AID levels, or by affecting
downstream repair processes, we chose to investigate if AID function at the switch
region was affected by directly measuring the mutational load.

Although the repetitiveness of the core switch region makes sequencing difficult,
the 5’ end of Sµ can be assessed for AID-induced mutations (figure 21a) and is
representative of AID targeting of the core switch region (Barreto, Reina-SanMartin, Ramiro, McBride, & Nussenzweig, 2003), (Xue, Rada, & Neuberger, 2006),
(Guikema, et al., 2007), (Jeevan-Raj, et al., 2011).

Using mutational analysis by paired-end deep sequencing (Mut-PE-seq)
(Robbiani, et al., 2015), (Wang, et al., 2016), we analyzed the mutational load at
the 5’ Sµ region in CH12 clones under activated and non-activated conditions. We
found a statistically significant reduction in mutations in the Zmynd8 KO clonal cell
lines (figure 21b). Increased mutation rates are not evenly distributed, but instead
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are concentrated at certain residues (figure 21c). These residues are RGYW motifs
or other potential targets for AID.
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Figure 21: AID Targeting of 5’ Switch regions
(A) Schematic representation of Eµ-Sµ-Cµ region with footprint of AID-induced
mutations (adapted from Xue J Exp Med 2006).
(B) Chart depicting cumulative mutation frequencies as determined by MutPE-Seq
at 5’-Sµ in gRNA targeted CH12 cells: two WT clones of CH12 (WTc-1, WTc-2),
an AID-/- clone (AID-KO), and three Zmynd8-/- clones (KO-1, KO-2, KO-3). Cells
were either left unactivated or activated for 48 h with IL-4, TGF-β, and CD40.
(C) Representative charts of the relative mutation frequency organized by
nucleotide position in the measured 5’-Sµ region in Mut-PE-seq. CH12 clones for
WT, AID-/-, and two Zmynd8-/- KO’s are shown.
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6.3 Zmynd8 Distribution in the IgH locus

Zmynd8 deficiency in CH12 cells leads to a decrease in AID targeting at Sμ.
Possible explanations for this could be an interaction directly with AID, alterations
in transcription at the IgH locus that affect AID targeting, or changes in epigenetic
marks at the IgH locus. All of these possibilities would be mediated by Zmynd8
occupancy at the IgH locus.

To explore Zmynd8 occupancy at the IgH in CH12 cells, we performed chromatin
immunoprecipitation coupled with high-throughput sequencing (ChIP-Seq). We
found that ZMYND8 associates with the Igh locus in activated CH12 cells, and it
binds the 5' Eμ and 3'RR (regulatory region) enhancers (Fig. 22a). Eμ and 3’RR,
are located at 5’ of Sμ and 3’ of Ca, respectively (Birshtein, 2014), (Perlot & Alt,
2008), and the 3’RR is a prototypical super-enhancer (Pinaud et al., 2011).

Because Zmynd8 depletion has been previously shown to result in enhancer
overactivation as measured by increased transcription of enhancer RNA (eRNA)
(Shen, et al., 2016), we asked if Zmynd8 deletion affects transcription of the IgH
enhancers. By reanalyzing the rRNA depleted, RNA-seq data in CH12 cells, we
found that the enhancers HS1,2 and HS3B within the 3’RR exhibited higher levels
of eRNA transcription (Fig. 22b) (Fig. 22c).
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To isolate if the increased levels of eRNA represented an increase in transcription
or a decrease in degradation, we assessed the occupancy of RNA PolII at the IgH
locus via ChiP-seq. We found that consistent with increased eRNA production,
there was more PolII loading at the 3’RR core enhancers, HS1,2 and HS3B (Fig.
22d, Fig 22e), in CH12 Zmynd8 KO cells.
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Figure 22: Zmynd8 and Pol II Distribution in the IgH Locus
(A) ZMYND8 occupancy at the Igh locus in WT and Zmynd8 -/- CH12 cells. A
schematic representation of the murine Igh locus (Chr12: 113,175,000113,441,797) showing location of enhancers and S regions within the locus is
represented below. Data are representative of two independent experiments.
(B) Heat map showing Igh 3’ RR enhancers (hs4; hs1,2; hs3b; hs3a) differential
transcript expression as determined by RNA-Seq in WT cells (WT bulk and clonal
derivative WTc) and two Zmynd8-/- CH12 clones. Cell were either left unactivated
or stimulated for 48h with aCD40, TGFb and IL-4. Expression counts are rownormalized by z-score. Three independent RNA-Seq replicates per sample are
shown
(C) Bar graphs depicting relative transcript levels at hs4, hs1,2, hs3b, hs3a.
(D) Top: RNA Pol II loading at the Igh locus (Chr12: 113,175,000-113,441,797) in
activated WT and Zmynd8-/- CH12 cells. Bottom: ChIP-Seq tracks overlay at
regions encompassing Ea and 3’RR enhancers. Regions zoomed-in in the insets
were defined based on the location of ZMYND8 peaks from Zmynd8 ChIP-Seq
(E) RNA Pol II loading quantification at regions highlighted within the insets in
panel A. Numbers above columns represent the ratio of RNA Pol II loading in
WT to loading in knock-out cells
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6.4 Genomic Distribution of Zmynd8

Zmynd8 is a histone mark reader, which localizes to promoters and enhancers in
several cell lines. Zmynd8 forms an interaction network with RNA Polymerase II
(Pol II) (Malovannaya, et al., 2011). Specifically, Zmynd8 binds to Pol II in a DNA
dependent

manner (Adhikary, et

al.,

2016). Additionally,

Zmynd8

co-

immunoprecipitates with the proximal-paused form of Poll II (CTD S5P), and not
the elongating form of pol II (CTD S2P) (Jonkers & Lis, 2015) (Figure 23a).
Consistent with this observation, Zmynd8 primarily localizes to the promoter
regions of genes in the DU145 prostate cancer cell line (Li, et al., 2016), and we
confirmed the Zmynd8 enrichment at promoter regions (57.49%), but also distal
intergenic regions (17.85%) in CH12 cells (figure 23b). Taken together with
Zmynd8’s function in transcriptional alteration (Li, et al., 2016), transcriptional
repression (Poleshko, et al., 2010), (Shen, et al., 2016), (Spruijt, et al., 2016),
(Zeng, Kong, Li, & Mao, 2010), and it’s association with the histone K14Ac marker
(Savitsky, et al., 2016), which indicates actively transcribing genes (Agalioti, Chen,
& Thanos, 2002) [specifically H3K14ac], (Eberharter & Becker, 2002) [histone
acetylation broadly] we postulated that Zmynd8 interacts primarily with promoters
and enhancers genome-wide.

To test this, we compared the occupancy of Zmynd8 with actively transcribing
genes (marked by H3K4me3) and active enhancers (marked by H3K4me1, and
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H3K27ac) (Calo & Wysocka, 2013). 72.27% of Zmynd8 peaks co-localize with
H3K4me3 and H3K4me1 (figure 23c). When we compared Zmynd8 peaks with
active enhancers (H3K27ac, and H3K4me1), 84.46% of the active enhancers also
co-localized with Zmynd8 (figure 23d). We concluded that the Zmynd8 binding of
the enhancer Eμ and super-enhancer 3’RR in CH12 cells is representative of
genome-wide Zmynd8 binding.
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Figure 23: Genomic Distribution of Zmynd8
(A) Schema of c-terminal domain phosphorylation of RNA polymerase II (adapted
from Jonkers and Lis Nature Reviews 2015). The RNA Pol II complex is recruited
to the transcription start site (TSS) of genes. A key regulatory step is the ser-5
phosphorylation at which point the Pol II is paused at the promoter proximal region.
Upon ser-2 phosphorylation, Poll II is released to begin productive elongation.
(B) Genomic distribution of ZMYND8 ChIP-Seq peaks in CH12 cells. Data are
representative of two independent experiments.
(C) Venn Diagram of the overlap between Zmynd8, H3K4me3 and H3K4me1
peaks.
(D) Venn Diagram of the overlap between Zmynd8, H3K27ac and H3K4me1
peaks. Note: the area with 3979 and 732 represents the overlap between H3K27ac
and H3K4me1 peaks and corresponds with enhancers.
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Chapter 7: ZMYND8 in Primary B Cells

7.1 Zmynd8 Mouse Generation and Characterization
To continue the investigation of CSR and Zmynd8 we decided to generate Zmynd8
deficient primary B-cells. Zmynd8-/- mice were previously reported to be embryonic
lethal and heterozygotes had several altered phenotypes including decreased
bodyweight and decreased caudal vertebrae number. The European mouse
mutant cell repository (EUCOMM) had frozen ES cells with a potential conditional
knockout of Zmynd8 (Zmynd8tm1a(EUCOMM)Wtsi) (Gene: Zmynd8, n.d.). By first
crossing the reconstituted mice with a FLPeR (Flipper) mice (Farley, Soriano,
Steffen, & Dymecki, 2000) the two loxP sites flanking the second exon of Zmynd8
(Figure 24a) could be exposed and the conditional knockout generated. To
selectively delete Zmynd8 in B-cells, we bred the Zmynd8f/f mice to CD19cre/cre mice
(Rickert, Roes, & Rajewsky, 1997). Zmynd8 appeared to be deleted in primary Bcells after 72 h stimulation with LPS and IL-4 (figure 24b). CD19 expression
initiates at the pro-B cell stage and therefore B cells in the Zmynd8f/f CD19cre/+
develop without Zmynd8. The lack of Zmynd8 does not affect B cell development
(figure 24c –representative flow cytometry plots; figure 724d –summary
experiments).
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Figure 24: Zmynd8 Mouse Generation and Characterization

(A) Vector map of KO first allele (reporter-tagged insertion with conditional
potential). Adapted from IMPC (international mouse phenotype consortium).
(B) Western blot analysis of whole cell extracts from Cd19Cre/+ and
Zmynd8F/FCd19Cre/+ B cells 72 h after stimulation with LPS and IL-4. Triangles
indicate threefold dilution. Data are representative of three independent
experiments.
(C) Representative flow cytometry analysis of lymphoid tissues from Cd19Cre/+ and
Zmynd8F/FCd19Cre/+ mice.
(D) Summary graphs for six mice per genotype.
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7.2 ZMYND8 and CSR in Primary B Cells

In chapter 7.1 we showed that Zmynd8f/f mice can successfully delete Zmynd8
protein in B cells under the CD19 cre allele. Like the effect in CH12 cells, Zmynd8
deletion in primary B cells also leads to a reduction in CSR (figure 25a). This effect
persists at activation times from 48 h to 96 h (figure 25b). We then confirmed that
that the CSR reduction is not due to altered cell proliferation as Zmynd8 deficient
B cells had a comparable number of cell divisions (figure 25c), but each cell
division had fewer switched cells (figure 25d). The expression of AID was
unchanged and thus also not responsible for the reduction in CSR (Figure 25e).
GLTμ levels were consistent between WT and Zmynd8f/f mice (Figure 25f). Unlike
the consistent downstream accepter GLT seen in CH12 cells, we found that the
acceptor GLTϒ1 or LPS and IL-4 stimulation in primary B cells was reduced (Figure
25g).
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Figure 25: ZMYND8-deficiency in primary B lymphocytes impairs CSR by
defective Igg1 GLT

(A) Representative flow cytometry plots measuring CSR to IgG1 timecourse after
stimulation of B lymphocytes with LPS and IL-4. Right: Summary dot plot for three
mice per genotype.
(B) Summary dot plot for three mice per genotype.
(C) Proliferation analysis of primary cultures of Cd19Cre/+ and Zmynd8F/FCd19Cre/+
B lymphocytes by CellTrace Violet dilution. Data are representative of three
independent mice per genotype
(D) Representative flow cytometry analysis showing the percentage of IgG1+ cells
per cell division in primary cultures of Cd19Cre/+ and Zmynd8F/FCd19Cre/+
splenocytes stimulated with LPS and IL-4 for 72 h. Cell division as measured by
CFSE dye dilution is shown on top.
(E) qPCR analysis for Aicda mRNA levels in B cells stimulated for 48 h with LPS
and IL-4. The data summarize three mice per genotype (error bars represent SD).
Cd19Cre/+ was assigned an arbitrary value of 1.0.
(F-G) qPCR analysis for Igµ (F) and Igg1 (G) germline transcript (GLT) levels in B
cells stimulated for 48 h with LPS and IL-4. The data summarize three mice per
genotype (error bars represent SD). Data was compared to Cd19Cre/+ which was
set at a value of 1.0.
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7.3 ZMYND8 and AID Targeting in Primary B Cells

We sought to repeat the analysis from chapter 6.2 in primary B cells. While we did
find WT (CD19Cre/+)B cells displayed a 4-fold increase in mutations at the 5’ end of
Sμ when compared against AID-/- B cells (Figure 26a), there was no difference
between the WT Zmynd8F/FCd19Cre/+ cells at 72 h or 96 h post activation.

144

Figure 26: Frequency of mutations at 5’Sμ in Zmynd8F/FCD19Cre/+
splenocytes
A) Graph depicting cumulative mutation frequencies as determined by MutPE-Seq
at 5’-Sµ in CD19Cre/+, Zmynd8F/FCD19Cre/+, and AID-/- splenocytes 72 h or 96 h after
activation with LPS and IL-4. Three independent experiments are shown with each
bar representing a different mouse.
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7.4 ZMYND8 and Chromosome Architecture at the IgH locus

In activated and resting B cells the 3’RR forms looping contacts with the regions
surrounding the 5’ Eµ enhancer (VDJ-Eµ). Upon activation, specific S regions are
recruited into the VDJ-3’RR loop in a cytokine-dependent manner (ThomasClaudepierre, et al., 2016), (Wuerffel, et al., 2007). This topological organization is
thought to facilitate both GLT expression and synapsis of recombining S regions.

Because ZMYND8 binds the 3’RR region we chose to investigate if the normal 3D
association within IgH was perturbed when ZMYND8 was removed. ZMYND8
binding to the Igh super-enhancers does not appear to contribute to the
establishment or maintenance of this architectural structure as determined by 4C
analysis (Figure 27a).
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Figure 27: ZMYND8-deficiency does not impair Igh locus chromatin
architecture

(A-B) Long-range chromatin looping interactions within the Igh locus in
unactivated and activated (48 h with LPS and IL-4) splenocytes from Cd19Cre/+ and
Zmynd8F/FCd19Cre/+ mice using a bait (black arrow) located within the ’RR
enhancer. 4C-Seq analysis of two mice per genotype are displayed.
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Chapter 8: Discussion

8.1 The IgH 3’RR: a key regulator of CSR
B cell development, survival, and function require the developmental
expression (Mårtensson, Almqvist, Grimsholm, & Bernardi, 2010), mature
expression (Lam, Kuhn, & Rajewsky, 1997), and continued signaling (Kraus,
Alimzhanov, Rajewsky, & Rajewsky, 2004), (Srinivasan, et al., 2009) of the B cell
receptor (BCR). It was discovered that initial BCR expression and by extension the
capability to produce antibodies was controlled by the 5’ enhancer of the IgH
constant region (Eμ) (Banerji, Olson, & Schaffner, 1983), (Gillies, Morrison, Oi, &
Tonegawa, 1983), (Neuberger M. , 1983). However, the enhancer is not required
for continued BCR expression after V(D)J recombination (Eckhardt & Birshtein,
1985), (Zaller & Eckhardt, 1985). This led to the model that the Eμ is essential for
activation of the IgH locus but not maintenance. A second enhancer was proposed
to account for the continued expression of the IgH locus. This was supported by
the discovery of a mouse myeloma cell line with impaired heavy chain transcription
which have a deletion downstream to the last constant region Cα, (Gregor &
Morrison, 1986). The 3’ RR was then identified in rats as a large enhancer 25 kb
downstream of the IgH locus (Pettersson, Cook, Bruggemann, Wiliams, &
Neuberger, 1990). The mouse homolog was identified piecemeal, as an assembly
of DNase I hypersensitive sites (HS). First identified was HS1,2 (Lieberson,
Giannini, Birshtein, & Eckhardt, 1991), then HS3a (Giannini, Singh, Calvo, Ding, &
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Birshtein, 1993) , (Matthias & Baltimore, 1993) just 3’ of Cα, and then HS4 at 33 kb
distant (Michaelson, Giannini, & Birshtein, 1995). Individually, the four 3’RR HS
sites comprising the 3’ RR are weak transcriptional enhancers compared to Eμ.
The strongest HS site, 4a possessed only 25% of the transcriptional strength of
the Eμ region while the 3a site barely had any transcriptional enhancement. The
difference in enhancement ability is even more striking when comparing the
relative size of the regions. Eμ is fully encompassed by a 700 bp region within the
JH-Cμ intron and all transcription factors bind to a core region of 220 bp
(Nikolajczyk, Dang, & Sen, 1999). In contrast, the 3’ RR extends 33 kb beyond the
3’ of the end of the last coding segment at IgH, Cα. Despite the size difference, the
3’ RR, as a whole, is a strong enhancer that drives expression of oncogenes in
translocations (Madisen & Groudine, 1994). The 3’ RR was thus identified as a
canonical locus control region as it causes lineage specific and defining gene
expression (Li, Peterson, Fang, & Stamatoyannopoulos, 2002), and is now
recognized as a super-enhancer (Whyte, et al., 2013).
Because the 3’ RR only altered IgH expression of mature B cells, i.e.
lymphocytes that had completed V(D)J recombination it was hypothesized that the
3’RR affected secondary immune diversification reactions, CSR and SHM. Cogné
and colleagues confirmed this for CSR by replacing the 5’ most HS site, HS3a,
with an expressed neomycin resistance gene (neoR) (Cogne, et al., 1994). This
reduced CSR to isotypes IgG2a, IgG2b, IgG3, and IgE, but not IgG1. The reducing
in CSR was accompanied by a reduction in the corresponding GLTs. However, the
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disruption of CSR was attributable to the neoR cassette and not deletion of the
HS3a enhancer per se (Manis, et al., 1998). Analogous to the emergent property
that all four enhancers are required to significantly upregulate IgH expression,
deletion of the entire 3’RR impaired CSR to all isotypes (Vincent-Fabert, et al.,
2010), but individual deletions had no effect on CSR (Manis, et al., 1998), (Bebin,
et al., 2010), (Vincent-Fabert, et al., 2009). It was hypothesized that the 3’RR
influences CSR independent of the specific HS sites, and instead acts via the multikb intervening DNA segments. Reconstituted HS sites, without the intervening
DNA, showed a heterogeneous effect, recovering CSR to IgG1 but not IgG3 (Le
Noir, et al., 2017). Furthermore, 5’ deletion of HS and intervening DNA from the 3’
RR (HS3a to HS3b) impaired CSR to IgG1, IG2a, and IgG3 but the remaining
HS4a and contextual DNA supported CSR to IgA and IgG2b at normal levels
(Garot, et al., 2016). The reported mutants and deficiencies in CSR were matched
by reductions in the corresponding GLTs. Thus, there appears to be a complex
emergent relationship between the HS sites, intervening DNA, and transcriptional
status in the impact on CSR (Figure 28). However, the mechanism of how the 3’RR
promotes germline transcription to effect CSR remains to be elucidated. In this
study we identified ZMYND8 as a novel effector of CSR acting by binding at the
3’RR to promote GLT.
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Figure 28: Comparison of Different IgH 3’RR mutants and CSR
Table 2: Comparison of Different IgH 3’RR mutants and CSR
Left column shows graphical representation of mutants. Grey circles represent WT
HS sites. Red circles are deletions of HS site along with any contiguous segments
in light grey. Blue circles are HS site replaced with neomycin cassette (along with
any contiguous segments in light grey). Yellow is inversion of HS site. Half arrows
indicate palindromic sequences. Second column is the genotype. Third column is
the source paper. Right columns (6) represent CSR to isotypes listed. Grey: CSR
for that isotype was not measured. Green: no difference between mutant and wild
type. Red: decrease in CSR. Orange: decrease proportionately smaller compared
to other isotypes in study.
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8.2 ZMYND8 and the IgH 3’RR
In this study we discovered that deletion of the chromatin reader ZMYND8
reduces CSR by down-regulating acceptor GLTs in primary B cells. Furthermore,
we excluded the possibility that ZMYND8 deletion may reduce CSR via impaired
donor GLT, AID targeting at Sμ, proliferation or impaired B cell development. The
IgH 3’RR similarly promotes CSR by facilitating transcription of GLT at the acceptor
switch region (Saintamand, et al., 2015). The IgH 3’ RR also does not impair GLT
at Sμ (Vincent-Fabert, et al., 2010), does not reduce AID targeting at Sμ
(Saintamand, et al., 2015), nor does it alter proliferation in actively switching B cells
(Cogne, et al., 1994). Due to these similarities we conclude that ZMYND8
deficiency phenocopies IgH 3’RR loss with respect to CSR in actively switching B
cells.

Furthering the correlation, we characterized the genomic distribution of
ZMYND8 via ChIP-seq and discovered that ZMYND8 co-localizes with the IgH
3’RR. This interaction is specific to the 3’RR as ZMYND8 does not associate with
the intervening switch or constant regions or the 5’ Eμ. We also discovered that
ZMYND8 association at the 3’RR can be divided into two sections: a first peak
covering the palindromic region delimited by the HS3a-HS1,2-HS3b (proximal),
and a second peak centered at HS4 (distal). The palindromic first region is a
conserved feature in mammals (D'Addabbo, Scascitelli, Giambra, Rocchi, &
Frezza, 2011) and SHM is primarily controlled by this region (Garot, et al., 2016).
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The HS4 (distal) module functions somewhat separately and supports CSR to IgA
and IgG2b independently (Garot, et al., 2016). The HS4 region also supports CSR
to IgA via the interaction with a lncRNA (Pefanis, et al., 2016). It would be
interesting to see if this lncRNA supports CSR to IgG2b and if other lncRNAs
interact with other HS sites. The division of ZMYND8 may point to the functional
differences between these regions.

8.3 ZMYND8 Potential Mechanisms of Action at the IgH 3’RR

Because ZMYND8 is highly enriched at the IgH 3’RR and phenocopies the
deletion of the IgH 3’RR in CSR through reduced GLT, we proposed that it might
act to promote CSR through a common mechanism. As a canonical superenhancer, the IgH 3’RR is thought to promote acceptor GLT at S regions by looping
into close proximity with the intronic promoters. The loop model of (super)enhancer
function dictates that transcriptional machinery and licensing factors are directed
to target regions by chromosomal folding over large distances (Li, Notani, &
Rosenfeld, 2016), (Kenter, et al., 2012). These conformations can be cell type
specific and stable or transient. B cells maintain a chromosomal loop between the
3’RR and VDJ- Eμ but this chromatin organization is absent in T cells (Wuerffel, et
al., 2007), (Ju, et al., 2007), (Sellars, Reina-San-Martin, Kastner, & Chan, 2009).
When B cells are activated, the 3’RR also comes into contact with the intronic
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enhancer specific for the S region being targeted. The degree of targeting is also
proportional to the degree of transcription elicited (Wuerffel, et al., 2007).

Like the Mediator complex (Med) which interfaces between Pol II and
transcription factors to promote the Pol II regulation including transcriptional
pausing and elongation (Allen & Taatjes, 2015), ZMYND8 associates with Pol II
(Malovannaya, et al., 2011), specifically with the paused (Ser-5-P) form of Pol II,
(Adhikary, et al., 2016). ZMYND8 also binds to gene promoters in DU145 cells (Li,
et al., 2016; Alt, Zhang, Meng, Guo, & Schwer, 2013), CH12 cells, and primary B
cells. It was recently shown that deletion of Med1 and Med2 reduces CSR by
reducing long-range chromosomal contacts between the Eμ and proximal
palindromic module of the 3’RR (Thomas-Claudepierre, et al., 2016). Additionally,
contacts between Eμ and downstream acceptor regions were reduced significantly.
Due to the occupancy of ZMYND8 at the 3’RR region, its association with
transcription machinery, and reduction in GLT we sought to investigate if ZMYND8
repressed GLT and CSR in a mechanism similar to the Med complex.

Using 3C (chromosomal conformation capture) and 4C (circular
chromosome conformation capture) experimental approaches we showed that the
VDJ- Eμ and 3’RR chromosome conformation is stable regardless of ZMYND8
presence. Similarly, the activation induced 3’RR contact with the intronic enhancer
of IgG1 did not decrease with ZMYND8 deletion. We concluded that ZMYND8
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does not promote GLT through contact of the 3’RR with the S region promoters. In
line with this, ZMYND8 must act downstream of IgH locus chromosomal
architecture remodeling and at a separate stage than the Med complex.
Instead of reducing chromosomal contacts between the 3’RR and the
acceptor switch regions, deletion of ZMYND8 might reduce GLT at the acceptor S
regions by decreasing RNA Pol II (Pol II) occupancy. Pol II is the eukaryotic RNA
polymerase that transcribes messenger RNA (mRNA), including many ncRNAs
(e.g. GLTs). Pol II is highly regulated to control transcription levels and maintain
transcription quality. Pol II is regulated at four potential stages: (1) recruitment to
the transcription start site (TSS), (2) entry into initial transcription—resulting in a
short elongation phase of 50-60 nucleotides, (3) pausing at this promoter proximal
region, and (4) productive elongation of the gene body or termination and release
(Jonkers & Lis, 2015). Pausing and elongation are characterized by
phosphorylation on the carboxy-terminal domain (CTD) of Pol II. Phosphorylation
at Ser-5 after entry pauses Pol II, while phosphorylation by positive elongation
factor B (P-TEFb) phosphorylates Ser-2, leading to productive elongation. As Pol
II transcribes through the gene body, Ser-5-P levels decrease and Ser-2-P levels
increase until termination and transcript release (Harlen & Churchman, 2017).
Pausing and release for elongation are key regulatory steps, both for production
of GLT and for targeting of AID.
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It has been extensively demonstrated that transcription is necessary for AID
targeting of switch regions (Yewdell & Chaudhuri, 2017). However, the process of
transcription differentially targets AID within the switch region. ChIP of Poll II at the
donor Sμ and at the acceptor Sγ3 in activated B cells showed that the spatial
distribution of Pol II is proportional to the mutation density (Pavri & Nussenzweig,
2011). In particular, Pol II occupancy increased from the TSS in the intronic
promoter and peaked at the S region 5’ boundary. High density Pol II was detected
throughout the S region and only decreased after the 3’ end (Rajagopal, et al.,
2009), (Wang, Wuerffel, Feldman, Khamlichi, & Kenter, 2009). This distribution
profile matches the regulation of Pol II with binding increasing from the TSS of the
intronic enhancer, accumulating at the proximal promoter site just downstream,
and continued occupancy in the S region/gene body until termination of the
transcript after the coding region. This Pol II density correlates with the mutational
density (Peters & Storb, 1996), (Rajagopal, et al., 2009). Pol II was also discovered
to be upstream of AID targeting as deletion of AID did not affect Poll II distribution
(Rajagopal, et al., 2009), (Wang, Wuerffel, Feldman, Khamlichi, & Kenter, 2009).
AID’s association with stalled Pol II is a general property and was detected in
promoter-proximal regions throughout the genome (Yamane, et al., 2011). Run on
analysis to detect transcribed RNA at the site of transcription also showed that Pol
II distribution associates with regions of active transcription. Thus, the correlation
of transcription apart from AID showed that Pol II occupancy is sequence and
transcription specific and not AID dependent.
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However, transcription occurs at literally thousands of places in the
genome, but only a small subset of regions (i.e. Variable genes and S regions) are
intended targets of AID. Instead, Pol II stalling is essential for AID targeting. This
was demonstrated because stalled Pol II accumulates at the promoter-proximal
region with AID off target genes c-Myc (Bentley & Groudine, 1986), (Krumm,
Meulia, Brunvand, & Groudine, 1992), IgK (Raschke, Albert, & Eick, 1991) and
Pim1 (Rohwer, Todd, & McGuire, 1996). Promoter pausing was proposed to act to
promote AID targeting by increasing ssDNA availability. This was corroborated by
the detection of ssDNA at the Variable regions and not constant regions of
activated Ramos B cells undergoing SHM, despite both regions being actively
transcribed (Ronai, et al., 2007). Pol II stalling was directly implicated in targeting
AID to Switch regions in particular and DNA in general with the discovery through
an unbiased shRNA that SPT5 was required for CSR (Pavri, et al., 2010). SPT5
had previously been found to associate with ssDNA and stalled Pol II (Gilmour,
2009), (Lis, 2007), (Rahl, et al., 2010). SPT was found to directly associated with
AID and SPT depletion decreased AID targeting to the intended IgH S regions and
known AID off target loci. Importantly, deletion of the 3’RR in mice has been shown
to reduce Pol II loading at the acceptor S regions as detected by ChIP of Ser-5-P
/ paused Pol II (Saintamand, et al., 2015). Thus, because AID targeting at the S
regions is dependent not only on the presence of processed transcripts as GLTs
but also the active transcription and pausing of Pol II in the generation of these
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transcripts, we sought to investigate if ZMYND8 depletion affected stalled Pol II at
the S regions.

Using a ChIP-seq approach for Ser-5-P Pol II on activated WT and
CD19Cre/+ ZMYND8

f/f

we discovered that despite the decrease in GLT from the

acceptor Sγ1 region, there is no decrease in paused Pol II at Sγ1. This implies that
there is no reduction in targeting of AID and resultant CSR due to insufficient Pol
II pausing. This is also the first evidence that ZMYND8 deletion does not exactly
phenocopy 3’RR deletion with respect to Pol II loading at the 3’RR. That is to say
ZMYND8 deletion retains stalled Pol II at acceptor switch regions, but 3’RR
deletion decreases stalled Pol II (Saintamand, et al., 2015). This discrepancy
brings up two questions. First, how are GLTs downregulated in ZMYND8
deficiency, if Pol II loading is unaffected, and second how could decreases GLTs
cause a reduction in CSR if Pol II pausing remains at normal levels? Decreased
GLTs could directly account for reduced switching independently of pausing via
intronic G-quadruplex structures (Zheng, et al., 2015). However, this still does not
mechanistically account for the actual decreased GLT in light of normally paused
Pol II. Because ChIP-seq of Ser-5-P Pol II and GLT measurement by RT-qPCR
only detects steady state levels, global run-on sequencing (Core, Waterfall, & Lis,
2008) could reveal if decreased steady state GLT was due to altered GLT
production. Alternatively, GLTs could be subject to increased degradation.
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If the reduction in GLT leading to a reduction in AID targeting at the switch
acceptor region is the sole explanation for reduced CSR we could empirically
demonstrate this by assessing the acceptor switch region for reduced AID induced
mutations. It is important, however, to note the technical limitations of doing so, i.e.
that acceptor switch regions are targeted less than the donor Sμ (Schrader, et al.,
2003) and effective measurement of AID activity can best be seen in a UNG-/MSH2-/- background (Xue, Rada, & Neuberger, 2006). Regardless, this would not
mechanistically account for ZMYND8’s function in reduction GLTs. Thus, although
we have been able to determine that ZMYND8 depletion reduces GLT, the
reduction in GLT is not due to impaired interaction of the 3’RR with acceptor S
regions or alterations in transcriptional machinery at the S regions as detected by
ChIP-seq.

Interestingly, ChIP-seq of Pol II revealed extensive binding to the 3’RR in
the absence of ZMYND8. We confirmed that this upregulated transcription at the
3’RR by rRNA depleted global RNA-seq in CH12 cells and and RT-qPCR in
primary B cells. This is consistent with ZMYND8’s ability to repress eRNA
transcription at enhancer regions (Shen, et al., 2016), and with its broader action
as a transcriptional regulator (Adhikary, et al., 2016), (Malovannaya, et al., 2011),
(Poleshko, et al., 2010), (Savitsky, et al., 2016), (Shen, et al., 2016), (Spruijt, et al.,
2016), (Zeng, Kong, Li, & Mao, 2010). Interestingly, despite increased deposition
of Pol II across the entire 3’RR, we only found increases in transcription at the
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HS3B and HS1,2 enhancers. It is possible that increased transcription at the 3’RR
results in increased AID targeting and recombinational deletion of the entire IgH
CH gene cluster leading to B cell death, a process termed locus suicide
recombination (LSR) (Peron, et al., 2012). This might be reflected in the lower
amounts of mature B cells circulating in 3’RR deficient mice, but that is primarily
due to the distal 3’RR encompassing the HS4 enhancer (Garot, et al., 2016).
Additionally, although LSR has been demonstrated to occur in B cells, it has yet to
be proven as a mechanism that regulates CSR. Instead, the reduction in CSR via
GLT reduction is more consistent with the known function of the IgH 3’RR and
other lines of evidence point to transcription deregulation at the 3’RR as the
mechanism.

Early investigations in the 3’RR showed that while singular deletions of HS
sites did not affect CSR, replacement of these sites with actively transcribing
neomycin resistance cassettes dramatically reduced CSR (Manis, et al., 1998)
(Cogne, et al., 1994). This implies that an increase in transcription at the 3’RR
region is causative for a reduction in CSR. Although the disruption of CSR via
activation of the 3’RR could be mechanistically distinct from the reduction in CSR
resulting from the entire deletion of the 3’RR (Vincent-Fabert, et al., 2010) –which
would inherently result in zero transcription, both models (i.e. up-regulation of 3’RR
transcripts via neomycin gene-insertion/Zmynd8 deletion and 3’RR deletion) cause
a reduction in GLTs at the acceptor S regions. This common feature implies that
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all three cases are mechanistically similar and are due to deregulation of the
normally transcriptionally repressed 3’RR. It is also likely that the eRNAs from the
3’RR in the case of ZMYND8 depletion do not act in trans to disrupt GLTs as the
similar disruption due to neomycin gene transcription points to a sequence
agnostic mechanism. This could potentially be tested in two ways. First,
transcription of 3’RR specific eRNA at a different locus could be tested if it disrupts
GLT and CSR. Additionally, stimulation of endogenous eRNA transcription with a
dead-Cas9 fused to an activator domain (La Russa & Qi, 2015) could be assessed
for reduction in GLT and CSR.

Ultimately the question remains, how does dysregulation of transcription at
the 3’RR lead to decreased CSR via a reduction in GLTs at the acceptor S regions?
With ZMYND8 deficiency, there is no reduction in chromosomal looping and no
reduction in stalled Pol II at acceptor S regions. Instead GLT reduction could result
from inhibited Pol II release and transcript elongation. A difference in actively
elongating transcripts could be detected with GRO-seq. A block to elongation
should increase the amount of stalled Pol II proportionately. However, such an
increase was not detected with ChIP-seq. This expected commensurate increase
in stalled Pol II may not occur if the amount of paused holoenzyme is optimized for
AID targeting of S regions and represents maximal loading potential under WT
conditions (i.e. there is no capacity to increase occupancy of paused Pol II at the
acceptor switch). In this case, Pol II initial binding and entry would be expected to
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decrease or Pol II off-loading/termination at the proximal pause step would be
expected to increase to maintain consistent enzyme levels. Correspondingly, it has
recently been shown that there is high Pol II turnover at paused genes (Krebs, et
al., 2017). ZMYND8 could mediate this directly as it interacts with the stalled form
of Pol II (Malovannaya, et al., 2011), (Adhikary, et al., 2016). Alternatively,
ZMYND8 could cause a reduction in GLTs through a secondary mediator.
ZMYND8 has been shown to not only be a transcriptional repressor as deletion
also decreases transcription of multiple genes (this study), (Li, et al., 2016). A
potential secondary mediator is the integrator complex, which controls the
termination of proximal-paused Pol II (Skaar, et al., 2015). This would be
consistent with what is currently known about ZMYND8 as it engages the integrator
complex (Malovannaya, et al., 2011), (Savitsky, et al., 2016).

ZMYND8 may also be an epigenetic regulator of the switch regions. The S
regions at the IgH locus undergo dynamic epigenetic modulation during activation
and CSR in B cells. Epigenetic marks H3K4me3 and H3K9ac/H3K14ac are
associated with the promoters of actively transcribing genes (Santos-Rosa, et al.,
2002), (Karmodiya, Krebs, Oulad-Abdelghani, Kimura, & Tora, 2012). In resting B
cells these marks correlate with the actively transcribed regions of the IgH locus,
specifically the Iμ promoter and the Sμ region (Chowdhury, et al., 2008), (JeevanRaj, et al., 2011), (Wang, Wuerffel, Feldman, Khamlichi, & Kenter, 2009), (Stanlie,
Aida, Muramatsu, Honjo, & Begum, 2010). Upon activation, these marks increase
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at the donor switch region Sμ and also appear on downstream acceptor switch
regions in proportional amounts to their activation evidenced by GLTs and
resultant CSR to the respective isotype. The epigenetically remodeling of the IgH
locus is dependent on activation, but independent of the action of AID (Kuang, Luo,
& Scharff, 2009). Transcription is intimately associated with epigenetic
modifications (Gates, et al., 2017), but the causal relationship between histone
modification, GLT, and CSR remains to be fully elucidated. The deletion of many
histone-modifying enzymes results in embryonic lethality, presumably due to the
complex transcriptional orchestration in development (Butler, Koutelou, Schibler,
& Dent, 2012). However, their effects could still be interrogated in B cells via
conditional deletions at later stages of development. From the few histone
methyltransferase/demethylase and acetyltransferase/deacetylases it is apparent
that GLTs and CSR can be somewhat decoupled from individual histone
modifications. For example, H3 acetylation at the acceptor Sε region was artificially
increased with a histone deacetylase inhibitor, but it could not increase Sε GLTs
and CSR to IgE in activated cells (Nambu, et al., 2003). Additionally, knockdown
of

the

FACT

(facilitates

chromatin

transcription)

complex

and

the

methyltransferase SPT16 impaired CSR (Stanlie, Aida, Muramatsu, Honjo, &
Begum, 2010). Although H3K4me3 markings were reduced, GLT and AID
expression remained normal. Additionally, depletion of the MLL3/MLL4
methyltransferases in B cells impaired CSR without reducing GLTs (Starnes, et al.,
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2016). Thus, epigenetic marks and GLTs may contribute in parallel pathways to
facilitate CSR.

The interplay between ZMYND8, GLT transcription, and epigenetic
modulation remains to be explored. It is known that ZMYND8 associates with
H3K4me0 and H3K4me1 in conjunction with H3K14ac and recruits the
demethylase of H3K4me3, JARID1D (Li, et al., 2016). ZMYND8 was also found to
recruit the demethylase KDM5C to demethylate H3K4me3 (Shen, et al., 2016).
Given the strong association of ZMYND8 for demethylated H3K4me it seems
paradoxical that depletion would affect the deposition of H3K4me3 on the switch
regions. Alternatively, it would be interesting to investigate if depletion of ZMYND8
increases H3K4me3 on the 3’RR. This could provide a mechanism for the increase
in Pol II loading and transcription.

8.4 RIF1 and ZMYND8

RIF1 Protein Interactome
The impetus for this study was to uncover novel components of the RIF1
interactome related to NHEJ and by extension CSR. RIF1 was found to be the only
necessary effector to prevent end-resection to promote NHEJ and CSR in
activated B cells (Escribano-Díaz, et al., 2013), (Chapman, et al., 2013), (Di
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Virgilio, et al., 2013). However, it is unknown how RIF1 engages the
phosphorylated S/TQ residues as the N-terminus of 53BP1 or how RIF1 protects
DNA DSB breaks to promote CSR. We originally proposed that a separate RIF1
interactor may mediate these functions.

Utilizing I-DIRT with sub-stochiometric amounts of cross-linking with
glutaraldehdye we identified the RIF1 protein interactome in B lymphocytes
undergoing CSR. The screen identified known interactors of RIF1 such as 53BP1
(Di Virgilio, et al., 2013), BLM (Xu, et al., 2010), Protein Phosphatase I (Hiraga, et
al., 2014), (Sukackaite, et al., 2017), and BACH1 (Tanaka, et al., 2016). We were
also able to identify interactors of interactors such as DYNLL1, which binds to
53BP1 (Lo, et al., 2005). Interestingly, BACH1 is more characterized as a
phospho-dependent binder of BRCA1. BACH1 binding to BRCA1 is necessary for
BRCA1 to exclude RIF1 from sites of DNA damage in S/G2 phase of the cell cycle
(Escribano-Díaz, et al., 2013). Additionally, activation of BACH1 in S phase
requires dephosphorylation (Kumaraswamy & Shiekhattar, 2007). It remains to be
studied if BACH1 associates with RIF1 in all cell cycle phases, if that interaction is
mutually exclusive to BRCA1 association based on phosphorylation status, and
what is the implication of the interaction with RIF1. For this study, we decided to
validate the novel interactors of RIF1 in promoting NHEJ by screening them for
promotion of CSR.
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RIF1 and CSR
RIF1 is an essential effector of CSR because it inhibits end-resection to
promote NHEJ of S region DSBs (Chapman, et al., 2013), (Escribano-Díaz, et al.,
2013), (Di Virgilio, et al., 2013). We found that ZMYND8 depletion reduced CSR in
the CH12 B cell lymphoma line and in primary B cells via a Rosa26Cas9/+ gRNA
somatic targeting model and via conditional deletion using CD19Cre/+ Zmynd8f/f. We
expected ZMYND8 to decrease CSR in a mechanistically similar way to RIF1 due
to their association in actively switching B cells and evidence of ZMYND8’s
function in DSB repair. Specifically, ZMYND8 was recently found to promote
homologous recombination repair of DSBs in regions of active transcription by
locally repressing

transcription

(Gong, et

al.,

2015), (Gong,

Clouaire,

Aguirrebengoa, Legube, & Miller, 2017), (Spruijt, et al., 2016), (Xia, et al., 2017),
(Kloet, et al., 2014). However, we were unable to document a significant effect of
ZMYND8 in the protection and repair of DSBs in ZMYND8-deficient CH12 or MEFs
cells, irrespective of the source of DNA damage (IR, PARPi, or CRISPR-Cas9).
This observation is consistent with our finding via co-immunoprecipitation that
ZMYND8 constitutively binds RIF1 in B cells undergoing CSR independent of DNA
damage or the ATM kinase. With respect to the action of ZMYND8 at the 3’RR and
its reduction in CSR, this is also consistent as the 3’RR is dispensable for pathway
choice during DSB resolution (Cogne, et al., 1994). Thus, despite the interaction
of ZMYND8 and RIF1 and their similar role to ensure efficient CSR, the two
proteins appear to enable CSR by completely different mechanisms: RIF1 by
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protecting DNA end-resection to promote NHEJ and ZMYND8 by facilitating
sufficient GLT from the acceptor S regions and by acting at the 3’RR.

ZMYND8 and CSR: Perspectives and Models

ZMYND8 is a chromatin reader of acetylated and demethylated histones. It
is thought to mediate transcriptional regulation by binding to and repressing the
activity of promoters and enhancers, (Adhikary, et al., 2016), (Malovannaya, et al.,
2011), (Poleshko, et al., 2010), (Savitsky, et al., 2016), (Shen, et al., 2016),
(Spruijt, et al., 2016), (Zeng, Kong, Li, & Mao, 2010). In accordance with these
reports, we found that ZMYND8 binds to the IgH super-enhancer (3’ RR) and
negatively regulates its transcription.

Mutation of the 3’RR in mice showed that it is required for CSR (Cogne, et
al., 1994), (Garot, et al., 2016), (Le Noir, et al., 2017), (Manis, et al., 1998), (Pinaud,
2001), (Saintamand, et al., 2015), (Vincent-Fabert, et al., 2010). The 3’RR
regulates CSR by promoting break formation via GLT transcription, RNA Pol II
pausing, AID targeting (Cogne, et al., 1994), (Garot, et al., 2016), (Le Noir, et al.,
2017), (Manis, et al., 1998), (Pinaud, et al., 2001), (Saintamand, et al., 2015),
(Vincent-Fabert, et al., 2010). However, the 3’RR does not affect repair or pathway
choice in DSB resolution in CSR (Cogne, et al., 1994). We found that ZMYND8
deficiency increases 3’RR transcription and phenocopies 3’RR deficiency, which
indicate that it regulates the 3’RR superenhancer. ZMYND8 deletion causes
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impaired CSR via reduction in acceptor GLT transcription in primary B
lymphocytes. We were not able to detect a significant decrease in Sμ GLT or
frequency of AID-induced mutations at 5’ Sμ in CD19Cre/+ Zmynd8f/f B cells. The
effect of ZMYND8 in primary cells only on the downstream GLT region Sϒ1 is
consistent with observations that the 3’RR controls GLT at acceptor S regions
preferentially (Saintamand, et al., 2015). However, deletion of ZMYND8 in CH12
cells also resulted in impaired CSR, but GLTs at the donor Sμ or the acceptor Sα
were unaffected. Instead we observed a reduction in AID-induced mutations at 5’
Sμ.

We believe technical limitations explain these discrepancies between Sμ
mutations and acceptor S region GLT. Although we were not able to detect a
significant decrease in the frequency of AID-induced mutations at 5’ Sμ in CD19Cre/+
Zmynd8f/f B cells, it is notable that (1) Zmynd8 is inefficiently Cre-deleted in this
strain and (2) the dynamic range of the mutation assay is low, specifically the
decrease in deletions at 5’ Sμ in CH12 cells is only ~2-fold which is consistent with
the small fold change caused by the knockout of known AID recruiter KAP1 in
primary B cells (Jeevan-Raj, et al., 2011). By increasing Cre delivery retrovirally to
primary B cells and pre-screening populations for Zmynd8 deletion we would
expect to more accurately assess AID mutations in primary B cells. Additionally,
by accounting for CSR status and proliferation stages (i.e. activated pre-switched
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IgM+ cells at division 5) as in (Reina-San-Martin, Chen, Nussenzweig, &
Nussenzweig, 2004) we could increase the sensitivity for AID mutation differences.

Furthermore, the discrepancy between the decrease in acceptor GLT in
primary B cells and the persistence of GLT at Sα in CH12 cells is consistent with
previous reports that deletion of the 3’RR in CH12 cells reduces CSR but does not
decrease GLT at Sα (Kim, Han, Santiago, Verdun, & Yu, 2016). GLT in CH12 cells
may not be an effective model to explore the 3’RR and CSR because (1) GLT at
Sα is constitutively expressed in CH12 cells (Nakamura, et al., 2006), and (2) B-1
cells switch efficiently to IgA in the absence of the 3’RR (Issaoui, et al., 2017).
Given that the originating lymphoma for CH12 cells is from the B-1a and not the
B-2 lineage (Arnold, Gridina, Whitmore, & Haughton, 1988), (Won & Kearney,
2002), this may explain why there is no defect in acceptor S region GLTs with 3’RR
dysregulation through ZMYND8 depletion.

Thus, when technical limitations are accounted for, ZMYND8 deficiency
phenocopies the effect of 3’ RR deletion as demonstrated by impaired acceptor
GLT and AID targeting of Sμ. It does so without altering the topological
organization.

Instead, the data indicates that ZMYND8 suppression of RNA Pol II loading
on the 3’RR enhancer and resultant absent eRNA production facilitates GLT
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transcription at the acceptor S region. The function and presence of elongating Pol
II at the acceptor region is most likely altered either through a lack of interaction of
paused Pol lI with ZMYND8 or through improper localization of a secondary factor
like the Mediator complex. In support of this model, replacement of individual
(hs1,2 or hs3a) or paired (hs3b and hs4) core enhancers with an actively
transcribed neomycin gene cassette resulted in a more severe defect in acceptor
GLT expression and CSR than deletion of the same modules (Cogne, et al., 1994),
(Manis, et al., 1998), (Pinaud, et al., 2001). Thus, deregulated transcription within
the 3’RR interferes with its activity and disrupts the physiological regulation of
germline transcription and CSR. Thus, we identify ZMYND8 as a key regulator of
3’ RR transcriptional activity under physiologic circumstances. In this context,
ZMYND8 promotes CSR by facilitating GLT and targeting of the acceptor switch
region.

Ultimately, we have defined the RIF1 protein interactome in actively
switching B cells. We found that the interactor, Zmynd8, a chromatin reader, is a
novel factor, required to support normal levels of CSR. ZMYND8 controls CSR by
modulating the transcriptional activity of the 3’ regulatory region super enhancer to
facilitate efficient germ-line transcription of the switch region. This represents a
new mechanistic step in the regulation of CSR.
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8.5 ZMYND8 Remaining Questions and Future Directions

Rif1 and ZMYND8 Association

It remains to be elucidated why ZMYND8 associates with RIF1. Despite
both functioning to promote CSR, they do so at completely different stages.
Categorically, RIF1 mediates CSR post DNA DSBs to engage the NHEJ pathway,
while ZMYND8 operates pre-break to promote GLT and efficient AID targeting and
DSB formation. Additionally, ZMYND8’s association with CSR appears to function
in relation to the 3’RR region while RIF1 associates primarily at the sites of DNA
damage. ZMYND8 identification as a factor in repressing transcription to promote
HR repair of DSBs was reminiscent of the original identification of RIF1 as a
component of the HR repair pathway (Buonomo, Wu, Ferguson, & de Lange,
2009), but we have determined through extensive investigation that ZMYND8,
unlike RIF1, does not impact NHEJ.

ZMYND8 may operate with RIF1 in a roll unrelated to DSB repair and CSR.
This is supported by our results that the interaction is DNA damage independent
and not affected by ATM inhibition. Aside from CSR, RIF1 functions to regulate
DNA replication timing (Cornacchia et al., 2012) and to prevent replication stress
induced cell death (Buonomo, Wu, Ferguson, & de Lange, 2009). The deregulation
of late replication firing in the absence of RIF1 was recently linked to the interaction
with protein phosphatase I (PP1), which phosphorylates the minichromosome
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maintenance complex MCM (Alver, Chadha, Gillespie, & Blow, 2017). Intriguingly
the MCM complex is also required for CSR (Wiedemann, Peycheva, & Pavri,
2016). ZMYND8 has also been implicated as being a protein enriched at the
replication fork (Dungrawala, et al., 2015).

Future studies could investigate the relationship between RIF1 and
ZMYND8 in replication stress and replication timing. Although the interaction
between RIF1 and ZMYND8 is independent of ATM, it could be mediated by ATR,
the kinase responsible for coordinating the cellular response to replication stress
(Flynn & Zou, 2011). In accordance with this hypothesis, ZMYND8 was shown to
be required for phosphorylation of CHK1 at S-345 (Gong, et al., 2015).

ZMYND8 CSR and the 3’RR

Although we have shown the ZMYND8 is a novel factor in CSR, promotes
efficient GLTs, and putatively operates through the transcriptional de-repression
of the IgH 3’RR, many questions remain. First, does ZMYND8 effect the role of
3’RR to promote SHM (Rouaud, et al., 2013). Also how does the de-repression of
transcription at the 3’RR mechanistically impact CSR. Transcriptional activity,
could be assessed independently of ZMYND8 through the dead-Cas9transactivator system mentioned above. Additionally, it remains to be seen if Pol II
turnover and elongation times at the acceptor switch regions are responsible for
the decrease in GLTs. Given ZMYND8’s association with various demethylases
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and strong interaction with chromatin marks it would also be appropriate to
characterize ZMYND8’s impact on the epigenetic markings, specifically H3K4me3,
H3K4me1,0, H3K14ac, and H3K27ac on the IgH locus.

ZMYND8 and Cellular Function
Numerous studies have implicated ZMYND8 in the repression of
transcription at DSBs to promote repair by HR. However, the method by which
transcriptional activity compromises DSB repair or the impact of failed repression
is unknown. The embryonic lethality of ZMYND8-/- mice implicates that the
consequences of failed repression at DSBs are immense, but cellular studies have
shown minimal impact of ZMYND8 depletion for cell survival or cycling. It is
similarly paradoxical that ZMYND8 has been implicated in preventing oncogenesis
and metastasis in cell culture, but high expression is also associated with poor
survival in the clinic. It would be relevant, then, to investigate in which cells
ZMYND8 is essential and under what conditions it is critical for cell survival and
function.
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Figure 29: Model of ZMYND8 Function at the IgH Locus and in CSR
Model of ZMYND8 function adapted from final publication: (Delgado-Benito, et al.,
2018). Note: post thesis defense, continued research revealed that ZMYND8 does
mediate SHM at the IgH locus. Regarding CSR, ZMYND8 binds to the 3’RR, and
in doing so excludes PolII there with a resultant reduction in eRNA production. This
corresponds to decreased acceptor GLT, while the default GLT, Su is unaffected.
CSR to all downstream isotypes is thereby reduced.
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Chapter 9: Methods
Methods adapted from: (Delgado-Benito, et al., 2018).
Mice
Rif1FH/FH (Cornacchia et al., 2012), Rif1F/F (Buonomo et al., 2009), Cd19Cre mice
(Rickert et al., 1997), and

AID-/- (Muramatsu et al., 2000) were previously

described. The conditional Zmynd8F allele was generated from crossing the knockout first allele with conditional potential Zmynd8tm1a (European Mouse Mutant
Archive, EMMA #05720) with the ROSA26Flpo deleter strain (The Jackson
Laboratory, JAX #007844). All experiments were performed in compliance with EU
Directive 2010/63/EU, and in agreement with protocols approved by Landesamt
für Gesundheit und Soziales (LAGeSo, Berlin), The Rockefeller University (NY),
and the National Institutes of Health (NIH) Institutional Animal Care and Use
Committees.

B cell cultures and retroviral infection
B lymphocytes were isolated from mouse spleens using anti-CD43 MicroBeads
(Miltenyi Biotec) and stimulated to undergo class switching with 25 μg/ml LPS
(Sigma-Aldrich) and 5 ng/ml of mouse recombinant IL-4 (Sigma-Aldrich) (CSR to
IgG1). CH12 cells (Nakamura et al., 1996) were stimulated to undergo CSR to IgA
with 5-15 g/mL aCD40 (BioLegend), 5 ng/ml TGF-b1 (R&D Systems) and 5 ng/ml
of mouse recombinant IL-4 (Sigma-Aldrich). pMX- ZMYND8-3XFlag retroviral
vector was generated by cloning the cDNA for murine ZMYND8 into pMX-IRES-
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GFP with a C-terminal 3XFlag tag. For CH12 infections with pMX-based retroviral
vectors, cells were subjected to 2 rounds of infection with amphotrophic retroviral
supernatant, with or without selection with 1 g/ml of Puromycin (Sigma-Aldrich),
followed by activation for 48h before analysis for CSR efficiency.

I-DIRT
B-cells from Rif1FH/FH and WT mice were isolated and cultured in SILAC medium
composed by RPMI (-Arg, -Lys) medium (Thermo Scientific), L-glutamine, sodium
pyruvate, Hepes, 50 μM 2-mercaptoethanol, antibiotic/antimitotic, 10% dialyzed
fetal bovine serum (Invitrogen), LPS, IL-4 and RP/14 (BD), and supplemented with
either

13C
6

L-arginine and

13C
6

L-lysine (Cambridge Isotope Laboratories) (heavy

medium; Rif1FH/FH culture), or non-labeled L-arginine and L-lysine (Sigma-Aldrich)
(light medium; WT culture). Cells were cultured in SILAC medium for 96 h to ensure
near-complete incorporation of the labeled amino acids. For IR treatment, cells
were exposed to an X-rays source at a rate of 278.2 Rads/min for 431 seconds
(20 Grays), followed by recovery at 37°C for 45 min.

Immunoisolation of RIF1FH-containing complexes
2.6x109 cells per culture (Rif1FH/FH and WT) were collected by centrifugation,
resuspended in 20 mM Hepes containing 1.2% polyvinylpyrrolidone (SigmaAldrich), protease and phosphatase inhibitor cocktails (Roche), 0.5 mM DTT, and
frozen in liquid nitrogen. Rif1FH/FH and WT frozen cells were mixed in a 1:1 ratio
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and cryogenically disrupted by wet milling in a Planetary Ball Mill PM 100 (Retsch).
The resulting frozen cell grindate was rapidly thawed in extraction buffer (20mM
Tris-Cl pH 8, 150 mM NaCl, 0.5% Igepal CA-630, 1.5 mM MgCl2, Benzonase,
protease and phosphatase inhibitor) supplemented with 2.5 mM Glutaraldehyde,
and quenched with 100 mM Tris-CL pH8.0 buffer after 5 min incubation. The lysate
was clarified by 10 min centrifugation at 13,000 rpm at 4°C, and immediately
incubated with magnetic beads (M-270 epoxy beads, Invitrogen) conjugated with
anti-Flag M2 antibody for 1 h at 4°C (Di Virgilio et al., 2013). The bead preparation
was then washed in extraction buffer, and RIF1FH bait and associated proteins
were eluted twice under native conditions by two rounds of incubation with 2.5
μg/μl 3XFlag peptide for 45 min at 4°C with shaking.

Mass spectrometric analysis
Rif1 baits and co-purifying proteins were resolved by 4-12% Bis-Tris gel and
visualized by Coomassie blue staining. The gel was divided into upper and lower
parts along the 39kDa molecular weight marker, with only the lower part fixed. The
protein containing upper and lower parts were cut into 5 and 1 regions respectively,
and the gel samples were subjected to in-gel tryptic digestion. Peptides were
extracted and purified, analyzed by LCMS using a Thermo Q Exactive Plus mass
spectrometer, with a Thermo Easy-nLC 1000 HPLC and a Thermo Easy-Spray
electrospray source. Identification and quantification of proteins was performed by
searching against a mouse protein sequence database with the MaxQuant
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software (version 1.2.2.5) (Cox and Mann, 2008). Protein H/(H+L) ratios were
derived using peptides’ H/L intensity values in MaxQuant output.

CRISPR-Cas9 somatic targeting and clonal derivative generation
gRNAs for functional screens for loss of CSR function in CH12 were cloned into
the U6 cassette of pX458 plasmid (pSpCas9(BB)-2A-GFP, addgene #48138)
according to standard protocols (Ran et al., 2013). For the loss of CSR screen, 36 gRNAs per candidate were cloned and individually tested. CH12 cells were
transfected with Cas9-gRNAs expressing constructs via electroporation with Neon
Transfection System (Thermo Fisher Scientific), sorted for GFP-positive cells after
40 h, and left to recover for 72 h before activation for CSR analysis. CH12 and
MEFs clonal derivatives were generated via electroporation with either single
gRNA and WT Cas9-based plasmid (pX458) or gRNA pairs and nickase Cas9based plasmid. In the latter case, tandem U6 cassettes were cloned into a mutated
version of pX458 expressing Cas9D10A. The location of the genomic sequences
targeted by the gRNAs used for the generation of these clonal cell lines is indicated
in Fig. 2A. Single GFP-positive cells were sorted in 96-well plates and clones were
allowed to grow for 12 days (CH12) or 17 days (MEFs) days before expansion.
Clones were validated at the level of genomic scar and protein expression. The
sequences of the gRNAs employed in these studies are listed in Table 3.

179

Table 3: CRISPR-Cas9 gRNAs
gRNA

Sequence

gZmynd8-1

AGAAAACGGCCCCGAAACGG

gZmynd8-2

AAGTCATTCCGTCCGTCCTG

gZmynd8 (nickase pair 1a)

GTCTTGGGGCGAATGGCCAT

gZmynd8 (nickase pair 1b)

ATTAAAAAGAAAAAGAAACC

gZmynd8 (nickase pair 2a)

GACACTTAGCGTGATAAACC

gZmynd8 (nickase pair 2b)

GAGACTGACATCGGAGCCAG

gAID

TGAGACCTACCTCTGCTACG

Ctrl gRandom-1

GCGAGGTATTCGGCTCCGCG

Ctrl gRandom-2

ATGTTGCAGTTCGGCTCGAT

gDSB-1

AGTTGTCATTGCTGAATATC

gDSB-2

CATGGATTTCTCCGGTGAAT

g53BP1 (nickase pair 1a)

CAGATGTTTATTATGTGGAT

g53BP1 (nickase pair 1b)

GAGTGTACGGACTTCTCGAA

gRif1 (nickase pair 1a)

AAGTCTCCAGAAGCGGCTCC

gRif1 (nickase pair 1b)

GAAGACCCCTCGGTGCCTCC

Cell lysates and Co-immunoprecipitation assay
Co-immunoprecipitation analyses were performed as for I-DIRT pull-down with the
only exception that protein elution from magnetic beads was performed by
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incubation with NuPage LDS Sample buffer (Thermo Fisher) supplemented with
50mM DTT for 10 min at 70C. Where indicated, 10 µM ATMi KU55933 (Tocris
Bioscience) was added 1h before irradiation. Western blot analysis of protein
levels was performed on whole cell lysates prepared by lysis in RIPA buffer. The
antibodies used for WB analysis are: anti-Rif1 (Di Virgilio et al., 2013), anti-Flag
M2 (Sigma-Aldrich), anti-ZMYND8 (Sigma-Aldrich), anti-γH2AX (Millipore), anti-β
Actin (Sigma-Aldrich), and anti-53BP1 (Bethyl).

Flow cytometry
For class switching assays, cell suspensions were stained with fluorochromeconjugated anti-IgG1 (BD-pharmigen), or anti-IgA (Southern Biotech). Samples
were acquired on a LSRFortessa cell analyzer (BD Biosciences) and analyzed with
FlowJo software. Analysis of B cell development and differentiation was performed
as previously described (Di Virgilio et al., 2013) using anti-CD21/CD35-FITC, antiIgD-FITC, anti-IgM-PE, anti-IgM-FITC, anti-CD43-PE (BD Biosciences) and antiCD23-PE, anti-CD3-PE and anti-CD19-APC (Biolegend) antibodies. For cell
proliferation analysis, primary B cells were pulsed with 2 µM carboxyfluorescein
succinimidyl ester (CFSE) or 5 µM CellTrace Violet (Thermofisher) for 10 min at
37C. For cell cycle analysis, CH12 cells were collected, fixed and permeabilized
using Fixation/Permeabilization Solution Kit (BD Biosciences) according to the
manufacturer’s instructions. BrdU pulse and staining was performed by using BrdU
Flow Kit (BD Biosciences) according to the manufacturer's instructions.
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Quantitative PCR
mRNA levels for AID and germline transcripts were measured as previously
described (Muramatsu et al., 2000; Pavri et al., 2010). 3’RR hs eRNA levels were
measured using the following primers:
Forward 5’- CATTCCCATGGTTCTGGGTAG-3’ and
Reverse 5’- CAAGAGGACATGACAGGAGATG -3’ for hs1,2;
Forward 5’-CATTGAGCTCCGGCTCTAAC-3’ and
Reverse 5’-CCCCTGTAGGGATCCTCCTAAT-3’ for 5’ hs3b;
Forward 5’-CATCCAGAGTCAAGGGGTGTC-3’ and
Reverse 5’-CTAGAACCACATGCTATCTAAGGGA-3’ for 3’ hs3b.

Immunofluorescence
iMEFs were grown on cover slips overnight. Cells were irradiated (10 Gy IR) and
allowed to recover for 90 min or 6 h. Upon fixation with 4% paraformaldehyde and
permeabilization with 0.5% Triton X-100, cells were stained with anti-γH2AX
(Millipore), rabbit anti-Rif1 serum (Di Virgilio et al., 2013), mouse anti-53BP1
(Upstate), mouse anti-Flag M2 (Sigma-Aldrich) or rabbit anti-ZMYND8 (SigmaAldrich) antibodies as primary antibodies, and with goat anti-rabbit Alexa546 and
goat anti-mouse Alexa488 as secondary antibodies. DNA was counterstained with
Pentahydrate (bis-Benzimide) (Hoechst). Images were acquired using inverted
LSM700 laser scanning confocal microscope (Zeiss).
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Clonogenic assay
For the colony formation assay following IR, iMEFs were plated in 60mm dishes,
irradiated after 24 hours with the indicated doses and incubated at 37°C in the
presence of 5% CO2. After 14 days, colonies were fixed with 15% acetic acid:
methanol (v/v) for 5 min and stained with 0.5% Crystal Violet (Sigma) for 30 min
for colony visualization. For the colony formation assay in the presence of PARPi
(Sigma), 10 nM or 1 µM PARPi was added 24 after seeding and cells allowed to
grow for 14 days before fixation, with fresh media and PARPi replenished on day
7. BRCA1-/- iMEFs were previously described (Bunting et al., 2010).

Metaphase analysis
MEFs were treated with 2 µM PARPi (Olaparib/AZD2281, Selleckchem) for 21 h,
and metaphase preparation and aberration analysis were performed as previously
described (Bunting et al., 2010).

End resection assay
Single guide RNAs targeting two sequences 2276 bp apart within the ROSA26
locus (Table S1) were cloned into pX458 plasmid (gDSB-1/2). CH12 cells were
electroporated with a 1:1 mix of gDSB-1 and gDSB-2 constructs using the Neon
Transfection System (Thermo Fisher Scientific), and allowed to recover for 24 h
before collection. Genomic DNA was extracted according to standard protocols
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and individual repair junctions were amplified using nested PCR reactions. The
first and second rounds of PCR were performed using
5’-CTGTTAGAGCATGCTTAAGGG-3’ Forward and
5’-TCACCATTAGGGCAAATGGC-3’ Reverse primers,
and
5’-GTAGTTACTTGGCAGGCTCC -3’ Forward
and 5’-AAAGTCATTCCACAGTTTGAC -3’ Reverse primers,
respectively. PCR products were extracted from agarose gel and sequenced.

CRISPR-Cas9-induced CSR assay
Constructs for expression of gRNA-Sµ and gRNA-Sa were generated by cloning
single guide RNAs directed to the 5’ Sµ and 3’ Sa regions respectively of the Igh
locus (Ramachandran et al., 2016) in tandem U6 cassettes on a modified pX458
plasmid backbone. Control construct was generated by cloning random sequences
not targeting the mouse genome in tandem U6 cassettes on same plasmid. CH12
cells were electroporated with the constructs using the Neon Transfection System,
and allowed to recover for 12 h before CSR analysis.

Mutational analysis
Primary cultures of splenocytes were collected at either 72 h or 96 h postactivation. gDNA extraction was performed according to standard protocols and
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MutPE-Seq at 5’ Sµ was performed as previously described (Robbiani et al., 2015;
Wang et al., 2017).

ChIP-Seq
ChIP-Seq for ZMYND8 and RNA Pol II were performed following protocols
previously described (Pavri et al., 2010; Yamane et al., 2013), and using antiZMYND8 rabbit polyclonal antibody (HPA020949, Sigma) and anti-RNA Pol II (4H8
abcam) antibody. FASTQ files were aligned against mouse genome (mm10) using
BWA mem (Li & Durbin, 2009). Processing and peak-calling of ChIP-Seq data
were accomplished with HOMER ChIP-Seq program (Heinz et al., 2010). Peak
annotation was done using R and ChIPseeker package (Yu, Wang, & He, 2015).

RNA-Seq
Samples used in RNA-Seq were cultured in activated and unactivated conditions
for 48 h. Cultured cells were collected by centrifugation and RNA was extracted
with AllPrep DNA/RNA Mini Kit (Qiagen). Ribosomal RNA was depleted using
Ribo-Zero Gold rRNA Removal Kit (Illumina). Libraries were prepared with TruSeq
Stranded Total RNA Library Prep Kit (Illumina). Three biological repeats were
performed and run in two lanes on the same flow cells on NextSeq High Output 75
SR (Illumina). For data analysis, reads were pseudo-aligned to an index created
from the Ensembl mouse GRCm38.p5 assembly and custom annotations of Igh
locus features. Transcript-level abundances were quantified using kallisto v0.43.0
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(Bray, Pementel, Melsted, Pachter, 2016), and subsequently summarized to the
gene-level using the R package tximport (Soneson, Love, Robinson, 2015).
Differential gene expression analysis was performed using DESeq2 (Love, Huber,
Anders, 2014).
4C-Seq
The 4C assay was performed as previously described (Qian et al., 2014). The bait
was amplified using the following primers:
5′-ACCACAGAGACCTCTGGATC-3′;
5′-GCATGAGCTGCAGATGGTAC-3′.
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